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INTRODUCTION 
Ischemic-hypoxic injury is a life-threatening condition that can be triggered by 
a heart attack, cardiac arrest, stroke, and neonatal hypoxia. In all of these condi-
tions, the patient’s survival depends on the duration of ischemic-hypoxic insult 
until blood circulation is re-established. Modern pharmacological intervention 
and diagnostic increase chances of survival. Despite these advances, however, 
the chance of a patient making a full recovery following ischemia reperfusion 
injury is still very low. There is a need to help these patients not only survive, 
but also have a normal quality of life. Ischemic-hypoxic injury is a complex 
condition where molecular events range from metabolic shift to the activation of 
various stress responses such as inflammation, endoplasmic reticulum (ER) 
stress and oxidative stress (Burwell et al., 2009; Eltzschig and Eckle, 2011; 
Murphy and Steenbergen, 2008; Nakka et al., 2010; Tajiri et al., 2004; Yellon 
and Hausenloy, 2007). Thus, a coordinated approach between different thera-
peutic approaches may increase the odds of survival and recovery. In this 
dissertation, the focus is on hypothermia, hydrogen sulfide (H2S) and lymp-
hangiogenesis. The aim was to study the therapeutic mechanisms that might be 
protective against ischemia reperfusion injury in order to enhance both our 
knowledge of ischemia reperfusion injury pathophysiology and mechanisms of 
protection. First, we demonstrate that mild hypothermia (32°C) activates major 
stress-inducible transcription factors nuclear factor erythroid 2–related factor 2 
(Nrf2) and hypoxia inducible factor 1 subunit alpha (HIF1A), affecting the 
antioxidant system and hypoxia response pathways, respectively (Eskla et al., 
2018). It is widely accepted that the therapeutic effects of hypothermia are due 
to metabolic depression caused by thermodynamic effects (Van’t Hoff’s rule) 
(Luscombe and Andrzejowski, 2006). However, our results suggest that hypo-
thermia activates specific signaling pathways leading to increased stress tole-
rance during oxygen restriction (Eskla et al, 2018). Next, we studied the mole-
cular mechanisms mediating the actions of hydrogen sulfide (H2S) in regulating 
mitochondrial biogenesis. We show here that not only does H2S  regulate  
mitochondrial biogenesis via AMP-activated protein kinase – peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (AMPK-PGC1α) but 
also that correcting H2S levels with SG-1002 could protect against heart failure  
by increasing cardiac mitochondrial content, improving mitochondrial respira-
tion, adenosine triphosphate (ATP) production efficiency, and cardiac function 
(Shimizu et al., 2018). Finally, we demonstrated that chronic myocardial 
ischemia and myocardial ischemia reperfusion both stimulate an endogenous 
lymphangiogenesis response. This study is one of the first to demonstrate that 
the endogenous lymphangiogenesis response is initiated during the first week 
after the onset of myocardial ischemia reperfusion injury. Furthermore, inhibi-
tion of the endogenous lymphangiogenesis response exacerbates ischemic heart 
failure (Shimizu et al., 2018). 
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In long term view, this dissertation aims to provide clues to additional oppor-
tunities that could be translated into more efficient therapeutic approaches 
against ischemia reperfusion injury. There is a surprisingly large gap between 
the broad application of clinical hypothermia and the understanding of its thera-
peutic mechanisms. Current results highlight the importance of the cellular 
stress response systems as potential targets of clinical hypothermia. It offers a 
novel framework for future investigations seeking to explore the therapeutic 
mechanisms of hypothermia in animal models and patients. Therapeutic strate-
gies to increase H2S have shown to be cardioprotective. The merger of H2S 
therapy and pharmacological agents targeting AMPK-PGC1α signaling pathway 
expand insight into strategies for treatment of heart failure. More importantly, 
this highlights H2S among the potential new therapies for treatment of heart 
failure. The lymphangiogenesis study imposes the necessity for further explora-
tion of the use of exogenous vascular endothelial growth factor C (VEGF-C) 
and its local delivery strategy over systemic delivery. In addition, combination 
of pro-lymphangiogenic factors with known modulators of inflammation and 
angiogenesis would extend therapeutic avenues to ischemia reperfusion injury 
treatment. 
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REVIEW OF LITERATURE 
Pathophysiology of ischemia reperfusion injury 
Normal tissue function requires continuous supply of oxygen and nutrients. 
Lack of blood flow causes an imbalance between the demand and supply of 
oxygen and nutrients (ischemia) resulting in profound tissue hypoxia and 
microvascular dysfunction (Visovatti et al., 2011). Surprisingly, restoring blood 
flow to the ischemic tissue, reperfusion, can trigger an additional cascade of in-
jurious events (Yellon and Hausenloy, 2007). For example, the histopatholo-
gical signs of injury after 3 h of liver or intestinal ischemia followed by 1 h of 
reperfusion are more profound than after 4 h of ischemia alone (Varadarajan et 
al., 2004; Parks et al., 1986). When a coronary vessel is occluded, intracellular 
respiration switches from aerobic to anaerobic (Figure 1). ATP production by 
mitochondrial oxidative phosphorylation depends on oxygen, and hypoxia leads 
to a rapid decrease in ATP production (Braasch et al., 1968), causing ADP, 
AMP, and adenosine to accumulate in the tissue. As a consequence of anaerobic 
glycolysis, hydrogen ions (Frank et al., 2012) and lactate accumulate (Braasch 
et al., 1968; Herdson et al., 1969; Visovatti et al., 2011). Lactate lowers intra-
cellular pH below 7.0. Intracellular acidification activates Na+-H+ ion exchanger 
to extrude H+ and results in intracellular Na+ overload. Consequent increase in 
intracellular Na+ activates the 2Na+/Ca2+ exchanger, which extrudes Na+ from 
the cell in exchange for Ca2+ entry, resulting Ca2+ overload. ATP depletion 
during ischemia also leads to inhibition of Na+K+ATPase and an efflux of K+ 
and an influx of Na+, Ca2+, Cl-, and H2O (Avkiran and Marber, 2002; Frank et 
al., 2012; Hausenloy and Yellon, 2013; Visovatti et al., 2011). 
 
 
Figure 1. The main proponents of myocardial ischemia reperfusion injury. mPTP – 
mitochondrial permeability transition pore, SR – sarcoplasmic reticulum, ROS – 
reactive oxygen species (Hausenloy and Yellon, 2013). 
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Mitochondria are crucial in cardio-protective mechanisms. The inner mito-
chondrial membrane is normally impermeable to ions and proteins and main-
tains its transmembrane potential. Acidic conditions during ischemia prevent 
the opening of mitochondrial permeability transition pore (mPTP), a non-speci-
fic pore in the inner mitochondrial membrane. If mitochondrial permeabilization 
is minimal, the cell may recover; if moderate the cell may die from apoptosis; if 
severe, the cell may undergo necrosis. Reperfusion can result in the opening of 
mPTP in response to oxidative stress and rapid change in pH. Reperfusion and 
reactivation of Na+-H+ exchanger results in the washout of lactate and H+ is 
transported into the extracellular space to normalize the pH in exchange for Na+. 
The restoration of the mitochondrial membrane potential drives Ca2+ into the 
mitochondria, which can also induce mPTP opening (Frank et al., 2012; Hau-
senloy and Yellon, 2013).  
Furthermore, ischemia triggers the activation of innate and adaptive immune 
responses and cell death programs (Eltzschig and Eckle, 2011). Thrombolytic 
therapy and primary percutaneous coronary interventions are treatments of 
choice for reducing acute myocardial ischemic injury, limiting myocardial 
ischemia size and improving clinical outcome. During reperfusion electron 
transport chain is reactivated, but instead of producing ATP it generates reactive 
oxygen species (ROS), such as superoxide anion  (Roberts et al., 1990; Kim et 
al., 1994; Visovatti et al., 2011). ROS are crucial mediators of ischemia reper-
fusion injury – accumulation of free radicals overwhelms the tissues’ anti-
oxidant capacity, leading to the oxidation and loss of function of various bio-
molecules (cellular injury) followed by organelle (e.g. mitochondrial) disrup-
tion, activation of pro-inflammatory pathways and, ultimately, cell death by 
necrosis or apoptosis (Frank et al., 2012; Lin et al., 2016; Visovatti et al., 2011). 
Accordingly, strategies for reducing oxidative stress by increasing antioxidative 
potential or reducing ROS production would be promising therapeutic 
approaches to mitigating the effects of reperfusion injury. 
Cardiac myocytes consume a large quantities of energy. Thus, it is not sur-
prising that these cells have high density of mitochondria. To maintain mito-
chondria and aerobic energy reserve, the cell has developed multiple mecha-
nisms that regulate mitochondrial homeostasis. The mitochondrial quality 
control system, consisting of mitophagy, fission and fusion, and biogenesis, is 
critically important in maintaining the fidelity of the heart under physiological 
and pathological conditions (Andres et al., 2015; Murphy et al., 2016; Dorn II et 
al., 2015). The cell has to identify damaged mitochondria, target them for selec-
tive mitochondrial autophagy and finally replace through mitochondrial bio-
genesis. When mitochondria are depolarized in response to various insults, 
PTEN-induced kinase 1 (PINK1) is stabilized on depolarized mitochondria. 
This leads to Parkin translocation to the outer membrane of mitochondria. Once 
Parkin translocates to the mitochondria, it facilitates the formation of auto-
phagosomes (Ding and Yin, 2012; Youle and Narendra, 2011). Autophagy 
receptors like BCL2 interacting protein 3 (BNIP3) and BCL2 interacting protein 
3 like (BNIP3L/NIX) localize on mitochondria and recruit autophagosomes to 
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damaged mitochondria by Parkin-independent manner (Zhang et al., 2008; Ding 
and Yin, 2012). Mitochondrial fission and fusion are important to repair da-
maged components of mitochondria for preserving mitochondria. Mitochondrial 
fusion is mediated by Mitofusin 1 (Mfn1), Mitofusin (Mfn2) and OPA1 mito-
chondrial dynamin like GTPase  (OPA1). The exchange of material between 
healthy mitochondria via fusion allows to preserve the better mitochondria. 
Mitochondria fission allows for elimination of the bad quality mitochondria and 
requires the recruitment of dynamin related protein 1 (Drp1) from cytosol to 
mitochondria (Twig et al., 2008; Vander Bliek et al., 2013). PGC-1α is a master 
regulator of mitochondrial biogenesis and energy expenditure (Kubli et al., 
2012; Fernandez-Marcos et al., 2011). PGC-1α regulates numerous transcription 
factors including peroxisome proliferator-activated receptor- α (PPARα), 
estrogen receptor–related α (ERRα) and nuclear respiratory factor 1 (NRF1) 
(Fernandez-Marcos et al., 2011). By regulating the transcriptional activities of 
these proteins, PGC-1α modulates genes involved in mitochondrial biogenesis 
and metabolic pathways. Mitochondrial content is significantly reduced in the 
failing hearts of both rodents and humans (Karamanlidis et al., 2010; Bayeva et 
al., 2013). Furthermore, downregulation of PGC-1α signaling has also been 
observed in experimental heart failure (Faerber et al., 2011). As such, under-
standing the mechanisms by which PGC-1α signaling is regulated in the heart 
could lead to the development of therapies aimed at inducing mitochondrial 
biogenesis and augmenting energy production in the setting of increased 
contractile demand (Bayeva et al., 2013). 
 
 
Protection against ischemia reperfusion injury 
Timely reperfusion is the only way to salvage ischemic injury. Although many 
treatments have been identified, the complexity of  ischemia reperfusion injury 
has made difficult to develop effective therapeutics against it. The most studied 
modalities against ischemia reperfusion injury include non-pharmacological 
strategies sush as ischemic pre-conditioning, ischemic post-conditioning, and 
remote ischemic conditioning, or pharmacological strategies (Davidson et al., 
2019). So far there have been no widely accepted therapies specifically tar-
geting reperfusion injury. This is, at least in part, due to our limited under-
standing of the mechanisms of ischemia reperfusion injury that could be ex-
ploited therapeutically. Therapeutic approaches can also be divided according to 
the time they are applied – before, during, or after ischemia. In this regard, it is 
important that a potential treatment involves combination of two or more 
mechanisms that are also appropriately timed. An ideal therapeutic strategy 
would restore oxygen supply to affected tissues while minimizing cellular stress 
during reperfusion. In this dissertation potentially therapeutic approaches such 
as therapeutic hypothermia, hydrogen sulfide, and lymphangiogenesis are 
studied. 
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Therapeutic effects of hypothermia 
Lowering of body temperature to preserve tissues is not a new concept. 
Numerous studies have shown that even small increases in body temperature 
(1–2°C) can significantly increase ischemic damage in rodent models (Wass et 
al., 1995; Dietrich et al., 1996; Kim et al., 1996). Conversely, mild therapeutic 
hypothermia of 32–35°C has shown consistent benefits against brain injuries in 
animal models (Barone et al., 1997; Colbourne et al., 1997; Ginsberg et al., 
1991; Maher and Hachinski, 1992). Furthermore, it also improves the neuro-
logic outcome of outside hospital cardiac arrest survivors (Bernard et al., 2002 
HACA, 2002) and neonatal hypoxia ischemia (Azzopardi et al., 2014; Wagner 
et al., 1999). A number of studies in both experimental animal models and 
patients have demonstrated the efficacy of moderate hypothermia initiated a few 
hours after severe ischemia or circulatory arrest in reducing the subsequent 
neuronal death and improving behavioral recovery (Bernard et al., 2002; Kawai 
et al., 2000; Miyazawa et al., 2003; Yanamoto et al., 2001). However, not all 
patients may benefit from therapeutic hypothermia. While it has been shown to 
provide protection in cardiac arrest and neonatal encephalopathy, clinical trials 
for cardioprotection in myocardial infarction showed beneficial effects only in 
limited subgroups (Chenoune et al., 2010; O’Neill and Dixon, 2004; O’Neill et 
al., 2005; Villablanca et al., 2016). 
Experimentally, the efficacy of hypothermia is highly dependent on the 
timing of initiation of cooling, its duration and depth. In most instances, the 
time of initiation should be less than 4–6 hours after the onset of ischemia. The 
body’s core temperature is cooled to 32–34°C for 12–24 hours. Methods of 
cooling include placing ice packs around the head, torso and neck, use of a cold 
air mattress, or placing an intravenous catheter and infusing cold saline. After 
about 24 hours slow re-warming begins. The re-warming process should be 
very gradual over approximately an eight-hour period to reduce possible side 
effects (Gupta et al., 2005; Yenari and Hemmen, 2010). Lowered body tempera-
ture decreases brain oxygen consumption, glucose metabolism, lactate produc-
tion, and accumulation of ROS. In addition, it preserves ATP, prevents apopto-
tic death, and inhibits inflammation. Hypothermia has also been shown to 
enhance angiogenesis and increase synaptogenesis  (Yenari and Han, 2012).  
Therapeutic hypothermia has been extensively studied in the laboratory, but 
most of the studies focus on its applications and efficacy in animal models. 
Consequently, little evidence is provided to advance our understanding of the 
underlying mechanisms. Ischemia and reperfusion are time-sensitive processes 
(Lee et al., 1999; White et al., 2000) and a major problem with therapeutic 
hypothermia is instituting it within a narrow window of opportunity. Ongoing 
clinical trials are focused on figuring out the depth (Chenoune et al., 2010; 
Duncker et al., 1996; Hamamoto et al., 2009) and duration (Colbourne et al., 
1999; Maier et al., 2001; Yenari et al., 2008) of hypothermia including how to 
standardize re-warming (De Georgia et al., 2004; Georgiadis et al., 2002; 
Polderman et al., 2002; Schwab et al., 1998), prevent and reduce side effects 
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(Kawai et al., 2000; Meloni et al., 2008; Schubert, 1995), and how to identify 
patients most likely to benefit from therapeutic hypothermia. Clinical trials and 
animal studies help to improve hypothermia treatment, but relatively little 
knowledge has accumulated on why hypothermia provides any protection at all 
apart from inducing metabolic depression (Luscombe and Andrzejowski, 2006). 
From a research standpoint, finding molecular mechanisms behind the thera-
peutic effect of cooling is of paramount importance, as it will pave the way for 
designing drugs targeting therapeutically relevant pathways without the con-
founding effects associated with body cooling. While there are many animal 
studies available to show benefits of applying hypothermia to mitigate 
ischemic/hypoxic damage, on the molecular level, most have focused on effec-
tor mechanisms related to innate immune response and apoptosis. In our study, 
we took a step back and asked whether hypothermia could modulate the respon-
siveness of mechanisms coping with cellular stressors.  
 
 
Cardioprotective effects of H2S 
H2S is now recognized as a novel gaseous signaling molecule along with nitric 
oxide (NO) and carbon monoxide (CO), although it was considered to be a toxic 
gas for hundreds of years. H2S is endogenously produced by three key enzymes: 
cystathionine β-synthase (CBS), cystathionine γ-lyase (CGL or CSE), and 3-
mercaptopyruvate sulfur transferase (3-MST) together with cysteine amino-
transferase (CAT) (Wang, 2002). CSE is the critical enzyme for H2S production 
in the cardiovascular system (Yang et al., 2011).  
A number of studies have demonstrated that endogenous and exogenous H2S 
have cardioprotective effects in myocardial ischemia reperfusion injury (Bian et 
al., 2006; Elrod et al., 2007; Sivarajah et al., 2006; Bliksoen et al., 2008; 
Johansen et al., 2006; Calvert et al., 2010b; Sodha et al., 2008; Osipov et al, 
2009; Ji et al., 2008), and cardiac disease may impair the endogenous synthesis 
of H2S further exacerbating injury (Jiang et al., 2005; Polhemus et al., 2014). In 
the cardiovascular system, H2S is involved in a wide range of protective 
mechanisms, such as the activation of anti-apoptotic (PI3K/Akt, ERK1/2/ 
MAPK, JAK-STAT) (Hausenloy et al., 2006; Hu et al., 2008; Luan et al., 2012) 
and anti-inflammatory pathways (eNOS and p38 MAPK) (Kondo et al., 2013; 
Kaiser et al., 2004), increased antioxidative capacity (Jha et al., 2008; Calvert et 
al., 2009), and preservation of mitochondrial function (Elrod et al., 2007; Wang 
et al., 2011). As mentioned previously, ROS production is increased during 
ischemia reperfusion injury. H2S is an inhibitor of cytochrome c oxidase and 
therefore inhibits respiration (Hill et al., 1984), which leads to decreased ROS 
production and preservation of mitochondrial structure and function (Calvert et 
al., 2010a; Aon et al., 2004; Chen et al., 2006). H2S also influences the 
levels/activation of a number of proteins related to mitochondrial biogenesis 
(PGC1α (Pan et al., 2014; Untereiner et al., 2016); AMPK (Minamishima et al., 
2009; Barr et al., 2015); endothelial nitric oxide synthase (eNOS) (Kondo et al., 
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2013; Polhemus et al., 2013; Kind et al., 2014) and there is evidence that 
mitochondrial content is higher in brains (Pan et al., 2014) and hearts (Calvert et 
al., 2010b) treated with exogenous H2S. These studies provided evidence for 
elevated mitochondrial levels in response to H2S treatment. It is not clear if the 
observed increase was due to a direct effect of H2S or was simply an indirect 
consequence of H2S altering injury. Therefore, the main goal of the current 
study was to address this issue by determining if H2S levels directly influence 
cardiac mitochondrial content under non-stressed conditions. Additionally, we 
sought to gain insights into the mechanisms by which H2S induces mito-
chondrial biogenesis in the setting of myocardial ischemia-reperfusion. 
 
 
Role of lymphangiogenesis in ischemia reperfusion injury 
Lymphatic vessels exist throughout the body in the same manner as blood 
vessels (Kerjaschki et al., 2014). They interconnect with blood vessels to form 
an elaborate system that functions in interstitial fluid drainage, lipid absorption, 
and immune cell responses (Zheng et al., 2014). Lymphangiogenesis, or the 
growth of lymphatic vessels from preexisting vessels, is the major if not the 
exclusive mode of lymphatic growth. Signaling via VEGF-C and VEGF 
receptor 3 (VEGFR3) is perhaps the most central pathway for lymphangio-
genesis. Disruption in lymphatic vessel formation during development (VEGF-
C or VEGFR3 deficient mice) leads to death (Karkkainen et al., 2004; Veikkola 
et al., 2001). Additionally, the loss of lymphatic function in humans (hereditary 
disease, lymphatic damage or surgical removal of lymph nodes) leads to lymph 
edema (Adams et al., 2007; Alitalo et al., 2005). This and other, more recent 
evidence have led to the understanding that lymphatic vessels are not simply 
passive conduits for interstitial fluid, but rather are essential for multiple 
physiological activities (Kerjaschki et al., 2014).  
The heart contains an elaborate network of lymphatic vessels, which serve to 
collect and return macromolecules, proteins, electrolytes, and fluid from the 
interstitial space to the circulation (Levick et al., 2010; Aspelund et al., 2016; 
Jones et al., 2011). As a result, the cardiac lymphatic system aids in the control 
of tissue pressure and edema formation (Aspelund et al., 2016). Interference 
with cardiac lymphatic flow (i.e. through obstruction) predisposes the heart to 
edema, inflammation, fibrosis, and infection (Kline et al., 1963). Additionally, 
impairments in cardiac lymphatic flow have deleterious affects on cardiac 
dysfunction in the setting of myocardial ischemia (Kline et al., 1964). Despite 
these well-documented actions, very little is known about the role the cardiac 
lymphatic system plays in the development of heart failure. Recent studies have 
begun to focus on this issue with the demonstration that myocardial ischemia 
initiates an endogenous lymphangiogenesis response (Klotz et al., 2015; Henri 
et al., 2016). Moreover, treatment with VEGF-C augments endogenous lymp-
hangiogenesis and leads to improvements in cardiac function (Klotz et al., 2015; 
Henri et al., 2016). Thus, it appears that therapeutic lymphangiogenesis serves 
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as a promising new treatment of heart failure. While these findings have laid the 
foundation for the concept of therapeutic lymphangiogenesis, there are a 
number of issues related to the kinetics and functional significance of the 
response that need to be addressed. Additionally, the consequences of inhibiting 
the endogenous lymphangiogenesis response have not been explored. Herein, 
we addressed these issues in well-defined murine models of ischemia-induced 
heart failure. 
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AIMS OF THE STUDY 
The general aim of this study was to gain additional insight into the molecular 
events triggered by ischemia and reperfusion. Ultimately a fused approach of 
different therapeutic modalities could help to achive optimal outcomes and 
lower fatality and morbidity of ischemia reperfusion injury. Based on the above-
presented analysis of literature the specific aims of present dissertation were: 
  
1. To survey the effect of hypothermia on selected cellular stress pathways with 
the potential to extend tolerance to ischemia reperfusion injury. 
2. To determine if H2S levels directly influence cardiac mitochondrial content. 
To gain insights into the mechanisms by which H2S induces mitochondrial 
biogenesis in the setting of myocardial ischemia reperfusion. 
3. To explore the role of cardiac lymphatic system in the development of heart 
failure and study the consequences of lymphangiogenesis response inhibi-
tion. 
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MATERIALS AND METHODS 
1. In vitro cell culture (I) 
1.1. Cell lines (I) 
In paper I, HeLa cells (CCL-2) were purchased from ATCC and used for gene 
expression, glutathione, cell viability, western blot and luciferase reporter acti-
vity analysis. HIF luciferase reporter HeLa stable cell line (SL-0023, Signosis) 
and nuclear factor kappa light chain enhancer of activated B cells (NF-κB) 
luciferase reporter HepG2 stable cell line (SL-0017, Signosis) were used for 
luciferase reporter activity assay and gene expression analysis. Antioxidant 
response element (ARE) luciferase reporter HepG2 stable cell line (60513) was 
purchased from BPS Bioscience and used for gene expression, cell viability, 
western blot and luciferase reporter activity analysis. Mouse embryonic fibro-
blasts (MEFs) (Millipore) were used for gene expression, glutathione, and cell 
viability analysis.  
All cell lines, except MEFs were cultured in low glucose Minimum Essential 
Media (MEM) (MEM-STA, Capricorn Scientific) supplemented with 10% fetal 
bovine serum (FBS) (2050-1, PAN Biotech), 1x penicillin/streptomycin (2007, 
Smart Media) at 37°C with a 5% CO2 atmosphere and then switched to 32°C 
incubator with 5% CO2 atmosphere during hypothermia experiment. 
 
 
1.2. Isolation of Mouse Embryonic Fibroblasts (I) 
To isolate Nrf2-KO (B6.129X1-Nfe2l2tm1Ywk/J, 0017009, The Jackson Labo-
ratory) MEFs, pregnant mice were sacrificed at 15.5 days post coitum (dpc) by 
cervical dislocation. Embryos were dissected into a 100-mm dish with 
phosphate buffered saline (PBS) (2002, Smart Media), head and red organs 
were removed, and washed with PBS three times. Embryos were placed in a 
clean Petri dish and the tissue was minced using a sterile razor blade. 1 mL of 
0.25% trypsin/ ethylenediaminetetraacetic acid (EDTA) (25200056, Gibco, 
Thermo Fisher Scientific) per embryo was added and Petri dish was incubated 
for 10 min at 37°C. After 10 min of incubation, cells were dissociated by 
pipetting up and down. Again, 1 mL of 0.25% trypsin/EDTA per embryo was 
added followed by 10 min incubation at 37°C. This step was repeated 3 times. 
Trypsin was inactivated by adding 1 volume of MEF medium. MEFs were 
cultured in high glucose Dulbecco’s Modified Eagle Medium (DMEM) (E15-
883, PAA) supplemented with 10% FBS, 1 mM sodium pyruvate (S11-003, 
PAA), 1x penicillin/streptomycin (1377475, Gibco, Thermo Fisher Scientific), 
and 2 mM Glutamax. Cells from 2 embryos were pooled in a 100-mm Petri dish 
coated with 0.1% gelatin and incubated overnight. Next day, media was 
changed and cells were grown to confluency. Passage 0 cells were frozen or 
continued to grow. 
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1.3. Treatments (I) 
In paper I, all treatments were performed for 8 hours at 37°C or 32°C. The fol-
lowing concentrations were used for treatments: tert-Butylhydroquinone (tert-
BHQ) (150–500 µM), DL-Sulforaphane (3 µM), N-acetylcysteine (8 mM), 
brefeldin A (5 µg/mL), tunicamycin (5 µg/mL), cobalt (II) chloride hexahydrate 
(CoCl2) (100 µM), and recombinant human tumor necrosis factor alpha (TNF-
α) (20 ng/mL). 
 
2. Materials (I, II, III) 
In paper I, tert-BHQ (112941), DL-Sulforaphane (S4441), brefeldin A (B7651) 
and tunicamycin (T7765) were dissolved in dimethyl sulfoxide (DMSO) 
(A3672; PanReac AppliChem) with final concentrations ranging from 0.01 – 
0.1%. N-acetylcysteine (A9165) and recombinant human TNF-α (570104) were 
dissolved in PBS. Cobalt (II) chloride hexahydrate (255599) was dissolved  
in milli-Q water. All compounds, except for recombinant human TNF-α 
(BioLegend) were purchased from Sigma Aldrich. 
In paper II, the orally active H2S-releasing prodrug, SG-1002, was provided 
by Sulfagenix (Cleveland, OH). SG-1002 was administered to mice in the diet 
(Purina 5001; Research Diets Inc., New Brunswick, NJ) to achieve a dose of  
20 mg/kg/day (Kondo et al., 2013). Mice received the diet for 4 weeks. Control 
mice received standard chow (Chow; Purina 5001) for the same duration. 
In paper III, recombinant human VEGF-CCys156Ser (752-VC-025/CF) was 
purchased from R&D Systems (Minneapolis,MN). The VEGFR3 inhibitor, 
MAZ51 (#676492) was purchased from Millipore Sigma (Burlington, MA). 
VEGF-C NAb (52393) was purchased from GeneTex, Inc. (Irvine, CA). 
Gelatin-based hydrogels were obtained from MedGEL (Kodaira, Tokyo, Japan) 
(Tabata et al., 1999; Yamamoto et al., 2003). 5-Bromo-2’-deoxyuridine (BrdU) 
(#B5002) was purchased from Sigma-Aldrich. 
 
 
3. Animals (II, III) 
In paper II, the following strains of mice on a C57BL/6J background were 
utilized: (1) C57BL/6J (Jackson Labs, Bar Harbor, ME), (2) Cardiac specific 
cystathionase-γ-lyase transgenic (CSE Tg+), (3) Cystathionase-γ-lyase deficient 
(CSE KO), (4) AMPKα2 floxed (Stock#: 014142, Jackson Labs, Bar Harbor, 
ME), (5) αMHC-Cre transgenic (Stock#: 011038, Jackson Labs, Bar Harbor, 
ME). CSE Tg+ were generated by ligating the full-length Mus musculus 
cystathionine γ-lyase cDNA to the murine α-myosin heavy chain (αMHC) pro-
moter, followed by injection of the DNA into newly fertilized mouse embryos 
(FVB/n background) (Elrod et al., 2007). The mice were then backcrossed to 
C57BL/6J for 9 generations. Global CSE KO knockout mice were generated by 
replacing exon 1 (including the ATG start codon), exon 2, and exon 3 with a 
neomycin selection cassette (Kondo et al., 2013). The mice were then back-
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crossed to C57BL/6J for 9 generations. Cardiac specific AMPKα2 deficient 
mice (αMHC-Cre+ x AMPKfl/fl) were generated by breeding AMPKf/f mice 
with αMHC-Cre+ mice. In all experiments, Wild-Type (WT) littermates were 
used as controls. Male mice between the ages of 8–10 weeks were utilized.  
In paper III, C57BL/6J mice (Male; 8–12 weeks of age) were used in all 
experiments.  
All experimental protocols were approved by the Institute for Animal Care 
and Use Committee at T3 Laboratories and conformed to the Guide for the Care 
and Use of Laboratory Animals, published by the National Institutes of Health 
(NIH Publication No. 86-23, revised 1996), and with federal and state regula-
tions. 
 
4. Patient samples (II) 
Left ventricular (LV) samples were procured from patients with advanced ische-
mic heart failure undergoing a heart transplant at Emory University in accor-
dance with Institution Review Board protocols. Additional non-failing heart fai-
lure samples were obtained from LifeLink. All patient identifiers were removed 
to strictly maintain donor confidentiality and anonymity. Both sample sets 
included male and female patients (Table 1). 
 
 
Table 1. Patient Characteristics 
Group Number Age % Female 
Non-Failing 6 53.5±3.8 66% (4/6) 
Heart Failure 10 56.0±2.6 40% (4/10) 
 
 
5. Protein extraction and Western blot analysis (I, II, III) 
In paper I, after washing with PBS, cells were lysed in 1x passive lysis buffer 
(E1941, Promega) with gentle shaking at room temperature (RT) for 15 minu-
tes. The extracts were centrifuged at 12,000 x g for 30 sec at 4°C and stored at  
-80°C. Protein concentration was determined with bicinchoninic acid (BCA) 
method (Pierce BCA Protein Assay Kit, Thermo Scientific) according to manu-
facturer’s protocol. Proteins extracted from HeLa-HIF stable cells were used to 
study HIF1Α protein expression in response to hypothermia (32 °C) or CoCl2. 
Proteins extracted from HepG2-ARE stable cells were used to study Nrf2 
protein expression in response to hypothermia (32 °C) or tert-BHQ. Protease 
inhibitors (78430, ThermoFisher Scientific) were added to the lysis buffer after 
removing an aliquot for the luciferase activity assay. Equal amounts of protein 
(8 µg) were electrophoresed and transferred to a nitrocellulose membrane using 
the NuPAGE Electrophoresis System (Life Technologies). Membranes were 
incubated overnight at 4°C with primary antibodies: rabbit anti-HIF1A antibody 
(1:2,000) (NB100-479, Novus) or rabbit anti-Nrf2 antibody (1:1,000) (ab62352, 
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Abcam) and mouse-anti beta-actin (1:10,000) (sc-47778, Santa Cruz) as a 
loading control. Next day, membranes were probed for 1 h at RT with fluore-
scent conjugated secondary antibodies goat anti-rabbit antibody (1:40,000 for 
rabbit anti-HIF1A antibody and 1:5,000 for rabbit anti-Nrf2 antibody) (35569, 
Jackson ImmunoResearch) and goat anti-mouse antibody (1:15,000) (A21057, 
Invitrogen). Western blotting signals were detected by using the LI-COR 
Odyssey CLx system (LI-COR Biotechnologies). Images were converted to 
grayscale and band intensities were quantified in Image Studio Lite v 3.1.4 (LI-
COR Biotechnologies).  
In paper II and III, whole cell, cytosolic, or nuclear fractions were obtained 
from heart homogenates as previously described (Calvert et al., 2009). Protein 
concentrations were measured with the detergent compatible (DC) protein assay 
(Bio-Rad Laboratories, Hercules, CA, USA). Equal amounts of protein were 
loaded into lanes of Criterion™ TGX (Tris-Glycine eXtended) Stain-Free 
PAGE gels (BioRad). The gels were electrophoresed and activated using a 
ChemiDoc MP Visualization System (BioRad). The protein was then trans-
ferred to a polyvinylidene fluoride (PVDF) membrane. The membranes were 
then imaged using a ChemiDoc MP Visualization System to obtain an assess-
ment of proper transfer and to obtain total protein loads. The membranes were 
then blocked and probed with primary antibodies (Supplemental Table 2, paper 
II) overnight at 4 °C. Immunoblots were next processed with secondary anti-
bodies (Cell Signaling) for 1 h at RT. Immunoblots were then probed with a 
Super Signal West Dura kit (Thermo Fisher Scientific) to visualize signal, fol-
lowed by visualization using a ChemiDoc MP Visualization System (BioRad). 
Data was analyzed using Image Lab (BioRad). The total protein images were 
used as loading controls. For each protein of interest, the portion of the protein 
load image corresponding to the molecular weight of the protein of interest was 
used as the loading control (Barr et al., 2015). 
 
6. Quantitative Real-time Reverse Transcription PCR (I, II) 
In paper I, cells were plated at a density of 1 million cells in 100-mm culture 
dishes or 400,000 cells in 6-well plate. On the next day, cells were incubated at 
22°C, 27°C, and 32°C to initiate hypothermia or kept at 37°C for various dura-
tions followed by extraction of RNA with TRIzol® reagent (15596026, Thermo 
Fisher Scientific). One microgram of total RNA was used for first strand cDNA 
synthesis using Random Hexamers (LGC Biosearch Technologies or N8080127, 
Invitrogen) and SuperScript III Reverse Transcriptase (18080044, Thermo 
Fisher Scientific). Every reaction was made in four parallel samples to minimize 
possible errors. All reactions were performed in a final volume of 10 μl, using  
5 ng of cDNA. Primers and probes for qPCR assay were purchased from 
Applied Biosystems or designed for the detection of specific transcripts (LGC 
Biosearch Technologies) (Supplementary Table S1, paper I). Expression level 
of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein 
zeta (Ywhaz) or hypoxanthine guanine phosphoribosyl transferase (HPRT) was 
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used as internal reference for MEFs or HeLa and HepG2 cells, respectively. 
Real-time qPCR was performed using TaqMan Gene Expression Master Mix 
(4369016, Thermo Fisher Scientific) or HOT FIREPol EvaGreen qPCR 
Supermix (08-36-00001, Solis BioDyne). qPCR reactions were run on (1) ABI 
PRISM 7900HT Fast Real-Time PCR System equipment (PE Applied Bio-
systems, USA) and quantified with the ABI PRISM 7900 SDS 2.2.2 software, 
(2) QuantStudio 12K Flex Software v.1.2.2 Real-Time PCR System equipment 
(Applied Biosystems, USA) and quantified with the QuantStudio 12K Flex 
Software v.1.2.2. 
In paper II, RNA was isolated using the RiboPure kit according to the 
manufacturer’s instructions (Ambion). Reverse transcription was performed in a 
standard fashion with QuantiTect Reverse Transcription Kit (QIAGEN) supple-
mented with DNase treatment. Taqman qPCR was carried out according to the 
manufacturer’s instructions using probe sets obtained from Thermo Fisher 
Scientific. 
 
7. Luciferase-reporter assay (I) 
HeLa cells and HepG2-NF-κB stable cells were seeded at a density of 50,000 
cells/well onto 12-well plates, grown overnight, and co-transfected with 100 ng 
renilla and 100 ng firefly luciferase vectors by Effectene Transfection Reagent 
(301425, Qiagen). The following luciferase vectors were used: HSV-thymidine 
kinase promoter (pRL-TK) (E2241, Promega), CMV immediate early enhancer/ 
promoter region (pRL-CMV) (E2261, Promega), 5x activating transcription 
factor 6 (ATF6) site luciferase reporter gene (p5xATF6-GL3) (11976, Addgene) 
or pd2-EYFP-N1 (EYFP-Enhanced yellow fluorescent protein) (Clontech). The 
activities of firefly and renilla luciferase were measured using the Dual Luci-
ferase Reporter Assay System (E1980, Promega) according to manufacturer’s 
protocols.  
Stable cell lines expressing luciferase reporter were plated at a density of 
80,000 cells/well in 12-well plates and grown overnight. After experimental 
treatment the cells were harvested and analyzed for luciferase activity using 
Firefly Luciferase Assay (30003-2, Biotium). 
The luminescence was quantified using the VICTOR Multilabel Plate Rea-
der (PerkinElmer). Luminometer was programmed to provide a 10-second pre-
read delay, followed by a 5-second measurement period. 
 
 
8. Glutathione levels (I) 
The levels of total glutathione and glutathione disulfide (GSSG) were evaluated 
in HeLa, wild type and Nrf2 KO MEFs using the GSH/GSSG-Glo™ Assay 
(V6612, Promega). Cells were plated at 10,000 cells/well in 100 μL culture 
media in 96-well luminometer-compatible tissue culture plates, grown overnight 
at 37°C in a 5% CO2 culture incubator, and subjected to normothermia (37°C) 
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or hypothermia (32°C) for 24 h. Luminescence was measured using the Tecan 
Sunrise machine.  
 
9. Cell viability assay (I) 
Cell viability of MEFs, HeLa and HepG2-ARE cells was determined using  
of cell proliferation reagent Water Soluble Tetrazolium salt 1 (WST-1) 
(05015944001, Sigma Aldrich). Briefly, cells were plated at a density of 
10,000/well in 100 μL culture media in 96-well plate. Next day, the cells were 
exposed to normothermia (37°C) or hypothermia (32°C) for 24 hours in a humi-
dified tissue culture incubator. After 24h, culture media was changed to treat the 
cells with tert-BHQ for 3 hours. Finally, WST-1 reagent was added to wells 
according to the manufacturer’s instructions and incubated for additional 2 
hours. Absorbance was measured at 450nm. Reference wavelength was 690nm. 
To qualify independent experiments for subsequent statistical analysis it was 
required that the effect of tert-BHQ on the viability of cells pre-incubated at 
37°C lie between 0.25-0.75 of the vehicle control viability. 
 
 
10. Microarray experiments (I) 
One million primary MEFs (Millipore) were seeded onto 100-mm culture 
dishes and grown (atmospheric oxygen, 5% CO2 at 37°C) in DMEM (high 
glucose 4.5 g/l, supplemented with 10% FBS and L-glutamine, PAA) until 60–
70% confluent. Hypoxia was initiated by lowering oxygen concentration to 1% 
in a multi-gas incubator (Sanyo). Hypothermia was initiated by lowering tempe-
rature in the incubator to 32 ºC. The experiment was carried out in five bio-
logical replicates per experimental condition. After 24 h, RNA was extracted 
from the cells by Trizol® (Life) followed by expression profiling according to 
manufacturer’s protocols. Briefly, 50 ng of total RNA from each sample was 
amplified using the OvationPico WTA system V2 (Nugene). Fragmentation and 
biotin labeling was done using the Encore-Ovation cDNA Biotin Module 
(Nugene). The labeled samples were hybridized to the Mouse Exon 1.0 ST array 
(Affymetrix). The arrays were washed and stained with phycoerythrin con-
jugated streptavidin (SAPE) using the Affymetrix Fluidics Station® 450, and 
the arrays were scanned in the Affymetrix Gene Array® 3000 scanner to gene-
rate fluorescent images, as described in the Affymetrix Gene Chip® protocol. 
Cell-intensity (CEL) files were generated in the Gene Chip® Command 
Console® Software (AGCC) (Affymetrix). 
 
 
10.1. Microarray data analysis 
Differential gene expression was estimated directly from CEL files using  
DEMI (Ilmjärv et al., 2014) as implemented in R package version 1.0 
(https://CRAN.R-project.org/package=demi). False discovery rate (FDR) ad-
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justed differential expression p-values were provided by the DEMI package 
using a variant of FDR method, which accounts for statistical dependence 
between the observed variables (Benjamini and Yekutieli, 2001). Differential 
expression estimates with FDR values below 0.001 were considered statistically 
significant. Ensemble gene ID-s of significantly differentially expressed genes 
were submitted to g:Profiler (Reimand et al., 2016) for functional interpretation. 
Lists of up- and down-regulated genes were submitted separately. KEGG path-
ways (Kanehisa et al., 2014) and TRANSFAC transcription factor binding sites 
(Wingender, 2008) with corrected p-values below 0.001 were considered as 
significantly over-represented in the gene list.  
 
 
11. Electron microscopy (II) 
Heart tissue was dissected along the muscle fiber while immersed in 2.5% 
glutaraldehyde buffered with 0.1 M sodium cacodylate (pH 7.2). Samples were 
stored in the fixative overnight at 4 °C. Samples were then washed with the 
same buffer and post-fixed in 1% buffered osmium tetroxide, dehydrated 
through a graded ethanol series to 100%, and embedded in Eponate 12 resin. 
Ultrathin sections were cut on a Leica UC6rt ultra-microtome at 70–80 nm and 
counter-stained with 4% aqueous uranyl acetate and 2% lead citrate. Sections 
were examined using a Hitachi H-7500 transmission electron microscope 
equipped with a Gatan BioScan CCD camera. 
 
 
12. Citrate synthase activity (II) 
Cardiac citrate synthase activity was measured spectrophotometrically in homo-
genates (Mo et al., 2012). 
 
 
13. Sulfide measurements (II) 
Hydrogen sulfide and sulfane sulfur levels were measured in heart tissue as pre-
viously described (Nicholson et al., 2013). Fresh tissue was homogenized in  
5 volumes of PBS (pH 7.4). For measurement of H2S, 0.2 mL of the sample 
homogenate was placed in a small glass vial (5182-0553, Agilent Technologies, 
Santa Clara, CA, USA) along with 0.4 mL of 1 M sodium citrate buffer, pH 6.0, 
and sealed. The mixture was incubated at 37 °C for 10 minutes with shaking at 
125 rpm on a rotary shaker (Fisher Scientific) to facilitate the release of H2S gas 
from the aqueous phase. After shaking, 0.1 mL of head-space gas was applied to 
a gas chromatograph (7890A GC System, Agilent) equipped with a dual plasma 
controller and chemiluminescence sulfur detector (355, Agilent) and a data 
processor. The carrier gas was helium with a flow rate of 2.4 mL/min. For the 
measurement of H2S released from bound sulfane sulfur, 0.1 mL of the sample 
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homogenates and 0.1 mL of 15 mM DTT in 0.1 mM Tris/HCl, pH 9.0, were 
placed in a in a small glass vial, sealed, and incubated at 37 °C for 50 minutes. 
After the incubation, 0.4 mL of 1 M sodium 4 citrate buffer was injected 
through the rubber stopper and the mixture was incubated at 37 °C for 10 
minutes with shaking at 125 rpm on a rotary shaker to facilitate the release of 
H2S gas from the aqueous phase. After shaking, 0.1 mL of head-space gas was 
applied to a gas chromatograph as detailed above. The amount of H2S is 
reported as nmol/mg wet weight. 
 
 
14. Immunoprecipitation (II) 
Heart homogenates were immunoprecipitated with an antibody to PGC-1α using 
the Dynabeads® Protein G Immunoprecipitation Kit according to manufactu-
rer’s instructions. The samples were then subjected to standard Western blot 
techniques and the membranes probed with antibodies to phosphoserine and 
acetyllysine. 
 
15. AMPK activity (II) 
The activity of AMPK was measured in homogenates prepared from heart 
tissue. The samples were first immunoprecipitated with a specific anti-
AMPKα2 antibody (abcam). An aliquot of the immunoprecipitated samples 
were incubated in a reaction buffer containing 12.5 mM Tris-hydrochloride 
(Tris-HCl) (pH 7.5), 2.5 mM β-glycerophosphate, 1 mM dithiothreitol,  
0.05 mM sodium orthovanadate (Na3VO4), 5 mM magnesium chloride (MgCl2), 
0.050 mM ATP, and 0.2 mM of SAMS (AMPK synthetic substrate peptide). 
The rate of adenosine diphosphate (ADP) formed from the incorporation of 
ATP in the synthetic peptide was then measured with the ADP-Glo Kinase 
Assay kit (Promega) according to the manufacturer’s instructions. Activity was 
expressed as ADP generated (in picomoles) per minute per milligram of protein. 
 
 
16. Sirt1 activity (II) 
The activity of cardiac Sirtuin 1 (Sirt1) was evaluated using the SIRT1 Activity 
Assay (catalog# ab156065, abcam). 
 
 
17. Mitochondria respiration and ATP (II) 
Cardiac fibers were isolated and permeabilized wtih saponin as previously 
described (Lehman et al., 2008). Respiration was monitored using a Clark-type 
oxygen electrode (Hansatech Instruments, Amesbury, MA) in the presence of 
pyruvate or palmitoyl-l-carnitine. To evaluate ATP synthesis, aliquots were 
taken from the respiration chamber over a 1-minute period after the addition of 
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ADP. ATP was then quantified with a bioluminescence assay using an ATP 
determination kit (A-22066; Molecular Probes, Eugene, OR). The rate of ATP 
synthesis was then normalized to the oxygen consumption rates measured over 
the time the aliquots were collected to obtain a measure of ATP synthesis 
efficiency (ATP/Oxygen ratio). This measurement reflects the ratio of state 3 
(ADP stimulated respiration) ATP synthesis rates to state 3 oxygen consump-
tion. A higher value indicates better efficiency. 
 
 
18. Myocardial ischemia reperfusion protocol and 
echocardiograph analysis (II, III) 
In paper II, mice were subjected to surgical ligation of the left coronary artery 
(LCA) followed by reperfusion for 2 weeks. Echocardiography was performed 
as previously described (Calvert et al., 2010b). 
In paper III, heart failure was induced either by permanent ligation of the 
LCA or by subjecting mice to 60 minutes of LCA occlusion followed by reper-
fusion for up to 4 weeks. Surgical ligation of the LCA was performed under 
anesthesia (ketamine, 100 mg/kg; sodium pentobarbital, 20 mg/kg) as pre-
viously described (Calvert et al., 2010b; Shimizu et al., 2016). All animals 
received prophylactic antibiotic therapy with cefazolin (20 mg/kg) and bupre-
norphine (0.05 mg/kg) for pain. A total of 185 mice were included in the present 
study after accounting for animal deaths. All mice were randomly assigned to 
the treatment groups. For the experiments examining the proliferation of lymph 
endothelial cells, BrdU (30 mg/mL) (Naqvi et al., 2014) was injected intra-
peritoneally once daily following the onset of myocardial ischemia until the 
time of sacrifice. 
Transthoracic echocardiography was performed at baseline and 4 weeks after 
reperfusion using the Vevo 2100 with a 38-MHz linear array scanhead (Shimizu 
et al., 2016). 
 
19. Gelatin-Based Hydrogel Preparation (III) 
Gelatin-based hydrogels were prepared according to the manufacturer’s instruc-
tion. In brief, to prepare gelatin hydrogels, 10μl of an aqueous solution con-
taining VEGF-CCys156Ser(125 µg/ml) (Shimizu et al., 2012), MAZ51 (25 mg/ml) 
(Benedito et al., 2012), VEGF-C NAb (0.5 mg/mL) or vehicle was dropped 
onto the freeze-dried hydrogels. The hydrogels were incubated at RT for at least 
30 minutes. The hydrogels are designed to release their content as they degrade 
with roughly 90% being released by 14 days. This results in the following 
doses: VEGF-CCys156Ser, 3.214 µg/kg/day; MAZ-51, 0.643 mg/kg/day, and 
VEGF-C Nab, 0.0218 mg/kg/day. After the onset of reperfusion, the gelatin 
hydrogels were placed on the surface of myocardium prior to the closing of the 
chest. 
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20. Histological Analysis (III) 
Hearts were harvested and fixed in 10% formalin and embedded in paraffin. 
Slices were cut at 7 µm and stained with Masson trichrome (Millipore Sigma 
(Burlington, MA) (Shimizu et al., 2012). Fibrosis area was quantitatively 
analyzed with NIH Image software. 
 
 
21. Immunofluorescence (III) 
Frozen sections (7 μm in thickness) were prepared and stained for anti-LYVE1 
(lymphatic vessel endothelial hyaluronan receptor 1) to detect lymph vessels 
(Shimizu et al., 2013). These were followed by incubation with secondary 
antibodies. Coverslips were mounted using Vectashield H-1500-4′,6-
Diamidino-2-phenylindole (DAPI)-containing medium (Vector Laboratories) 
(Shimizu et al., 2013). Images were acquired on a Leica DM6000. B lympho-
cytes were detected by staining sections with antibodies against CD45R (B220) 
and immunoglobulin M (IgM). Proliferating lymph endothelial cells were 
evaluated by staining sections with antibodies against BrdU and LYVE1.  
 
 
22. Inflammatory cytokines (III) 
The levels of TNF-α, interleukin 1 beta (IL-1 beta), and interleukin 6 (IL-6) 
were evaluated in heart homogenates using enzyme-linked immunosorbent 
assay (ELISA) kits (eBioscience, #88-7324-22, #88-7013-22, and #88-7064-22, 
respectively) according to the manufacturer’s instructions.  
 
 
23. Statistics (I, II, III) 
In paper I, data are expressed as mean ± standard error of the mean (SEM). 
Statistical analysis was performed with (1) Student’s t-test or (2) paired t-test 
for comparsion of biological replicates treated with tert-BHQ after normo-
thermic and hypothermic pre-incubation. 
In paper II and III, all data are expressed as mean ± SEM. The data was first 
evaluated for normal distribution using the D’Agostino and Pearson omnibus 
normality test. Subsequent, statistical significance was evaluated as follows: (1) 
unpaired Student t-test for comparison between 2 means; (2) a 1-way analysis of 
variance (ANOVA) with a Tukey test or Dunnett’s Multiple Comparison Test 
as the posthoc analysis for comparison among 3 or more groups; and (3) in 
paper II, a 2-way ANOVA with a Bonferroni test as the posthoc analysis for 
comparison among the means from groups of WT and AMPK KO mice. For the 
echocardiography data, a 2-way repeated measures ANOVA with a Bonferroni 
test as the posthoc analysis was used. The following comparisons were made 
separately: (1) baseline vs. post-baseline measurements for each group,  
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(2) differences between each group’s baseline measurements, and (3) diffe-
rences between each groups post-baseline measurements. The p-value for these 
evaluations was adjusted by applying the Bonferroni correction for multiple 
comparisons. A value of p < 0.05 denoted statistical significance and p-values 
were two-sided. All statistical analysis was performed using Prism 5 (GraphPad 
Software Inc). 
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RESULTS AND DISCUSSION 
1. Paper I 
1.1. Hypothermia extensively remodels gene expression 
Large-scale gene expression profiling of MEFs revealed 3240 up-regulated and 
962 down-regulated genes in response to mild hypothermia (Supplementary file 
1 – Microarray analysis, paper I). Bioinformatic analysis of regulatory sequence 
motifs identified 85 unique transcription factors with significantly over-repre-
sented binding sites in promoter regions of hypothermia-induced genes (Supple-
mentary file 1 – Microarray analysis, paper I). RNA-transport was the only 
enriched KEGG pathway among hypothermia-induced genes concordant with 
the notion that the two best-studied hypothermia-responsive genes (cold-indu-
cible RNA-binding protein and RNA binding motif protein 3 (Cirbp and 
Rbm3)) encode RNA-binding proteins (Danno et al., 1997; Fujita, 2000; Nishi-
yama et al., 1997). In comparison, using the same methodology on cells treated 
24h with 1% O2 hypoxia, which is known to extensively remodel gene expres-
sion (Elvidge et al., 2006; Manalo et al., 2005), resulted in the up-regulation of 
335 and down-regulation of 477 genes (Supplementary file 1 – Microarray 
analysis, paper I). Bioinformatic analysis identified three transcription factors 
(Hif1a, zinc finger and BTB domain containing 14 (ZF5) and Sp1 transcription 
factor (Sp1)) with significantly over-represented binding sites in promoter 
regions of hypoxia-induced genes (Supplementary file 1 – Microarray analysis, 
paper I). As expected, significant enrichment of genes related to HIF1 signaling 
pathway, glycolysis and pentose phosphate pathway was identified by functio-
nal annotation analysis of hypoxia-induced genes (Supplementary file 1 – 
Microarray analysis, paper I). These results demonstrate more widespread 
effects of hypothermia on gene expression than initially anticipated and present 
an extensive list of transcription factors, which are predicted to be hypothermia-
responsive (Supplementary file 1 – Microarray analysis, paper I). 
In order to provide an independent validation of the hypothesis that hypo-
thermia is able to activate gene expression, we performed reporter experiments 
in human cell lines transfected with CMV promoter driven luciferase. CMV 
promoter is a strong activator of gene expression in mammalian cells and con-
tains binding sites of several activating transcription factors including cAMP 
responsive element-binding (CREB) and activating transcription factor (ATF) 
(CREB/ATF), NF-κB, activator protein 1 (AP1), E26 transformation-specific or 
E-twenty-six (ETS) and SP1 (Meier and Stinski, 1996; Thrower et al., 1996). 
Based on the TRANSFAC database of transcription factor DNA binding motifs, 
we found 173 and 75 high confidence sites on CMV and HSV-TK promoters, 
respectively (Supplementary file 2 – TF binding sites, paper I). Bioinformatic 
analysis suggested that some transcription factors binding to the CMV promoter 
(most notably CREB/ATF1) had over-represented motifs in the promoters of 
hypothermia-susceptible genes as identified in the genome-wide expression 
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screen (Supplementary file 2 – TF binding sites, paper I). Luciferase driven by 
HSV-TK, a considerably weaker viral promoter, was used as an additional com-
parison. Mild hypothermia significantly induced the activity of both CMV and 
TK reporters  up to 2.5 fold and 1.8 fold, respectively, above the normothermic 
level (Figure 2). These results provide further evidence to suggest that mild 
hypothermia can act as an activator of gene expression. 
 
 
 
Figure 2. Effect of hypothermia (8h) on the activity of CMV (A) and HSV-TK (B) 
promoters as reported by renilla-luciferase in HeLa and HepG2 cells. Reporter activity 
in each cell line is normalized to the corresponding normothermic control group. Figure 
represents at least three independent experiments (n = 3-4) per cell line. Mean values 
(+SEM) are shown. *, p< 0.05; ***, p < 0.001.  
 
 
1.2. Mild hypothermia activates Nrf2 and HIF1 transcription factors 
As the discovery of therapeutically relevant effects of hypothermia is of primary 
interest, we proceeded to test whether hypothermia can induce responses, which 
are known to mitigate cellular stress. Production of ROS during hypoxia-reper-
fusion has been suggested as a possible mechanism of hypoxic injury (Burwell 
et al., 2009; Eltzschig and Eckle, 2011; Murphy and Steenbergen, 2008; Yellon 
and Hausenloy, 2007). We investigated whether hypothermia could activate the 
antioxidant system. Microarray analysis indicated that several genes of the 
glutathione, thioredoxin and sulfiredoxin systems were upregulated after 24h of 
hypothermia in wild-type MEFs (Supplementary file 1 – Microarray analysis, 
paper I). qRT-PCR revealed the upregulation of glutamate-cysteine ligase cata-
lytic subunit (Gclc) and thioredoxin reductase 1 (Trxr1) at 8h after the onset of 
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hypothermia (Figure 3A, C). Upregulation of Gclc, sulfiredoxin 1 (Srxn1) and 
glutathione synthetase (Gss) was evident at 24h of hypothermia (Figure 3B, E, 
F). The fact that Nrf2 is the master regulator of antioxidant gene expression 
prompted us to study hypothermia response in Nrf2-deficient MEFs. As ex-
pected, the expression levels of the studied antioxidant genes were significantly 
reduced in Nrf2-deficient cells. Gclc and Trxr1 did not respond significantly to 
hypothermia in Nrf2-deficient cells (Figure 3B, D). Srxn1 and Gss were signi-
ficantly induced by hypothermia even in the absence of Nrf2 (Figure 3E, F) 
suggesting that, in selected cases, hypothermia can induce antioxidant gene 
expression by Nrf2-independent mechanisms.  
 
Figure 3. Effect of hypothermia on the expression of antioxidant system genes (A-F). 
Cold-inducible gene Cirbp was used as a positive control for hypothermic effect (G). 
Effect of hypothermia on total cellular glutathione (H) and glutathione disulfide (GSSG) 
(I) in wild-type and Nrf2-deficient mouse embryonic fibroblasts. Figure represents three 
independent experiments (n = 3) per cell line. Mean values (+SEM) are shown.  
*, p< 0.05; **, p < 0.01; ***, p < 0.001; #, p < 0.0001 when compared with controls at 
37°C. 
?
?
?
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In order to ascertain whether the apparent induction of glutathione system genes 
could translate into relevant biochemical changes, cellular glutathione, the 
major intracellular antioxidant, was measured by the glutathione-S-transferase 
based enzymatic assay (Promega). Total glutathione, comprised of reduced 
(GSH) and oxidized forms (GSSG), was significantly higher in wild-type MEFs 
after 24h of hypothermia when compared to normothermic controls. The oppo-
site pattern was observed in Nrf2-deficient MEFs where total glutathione level 
was lower in hypothermic cells (Figure 3H). These observations suggest that 
Nrf2 is required for hypothermia-induced increase of cellular glutathione in 
MEFs. GSSG level was lower in hypothermic wild-type MEFs when compared 
to normothermic controls suggesting that hypothermia increases antioxidant 
potential while lowering oxidative stress (Figure 3I). GSSG was undetectable in 
Nrf2-deficient cells presumably due to the low level of total glutathione. Hypo-
thermic treatment of HeLa cells was associated with increased total glutathione 
(Figure 4A) and increase in the expression of GCLC and TRXR1 (Figure 4C–
D). Hypothermia had no effect on GSSG (Figure 4B) suggesting, once again, 
that hypothermia does not lead to elevated oxidative stress. To establish that 
hypothermic pretreatment can be protective, three different cell lines were 
subjected to 24 hours of hypothermia followed by oxidative stress and quanti-
fication of cell viability (Figure 5A–C). We found that in MEF and HeLa cells, 
hypothermic pretreatment mitigated the effects of oxidative stress resulting in 
higher viability when compared to normothermic pretreatment. In sum, we 
found evidence for increased levels of glutathione and cell-type dependent 
increase in the resistance to pharmacologically induced oxidative stress after 
hypothermic pre-incubation. 
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Figure 4. Effect of hypothermia (24h) on total cellular glutathione (A) and glutathione 
disulfide (GSSG) levels (B), and expression of key genes of glutathione (GCLC) (C), 
and thioredoxin systems (TRXR1) (D) in HeLa cells. Expression of cold-inducible gene 
CIRBP was used as positive control for hypothermic effect (E). Mean values (+SEM) 
from three independent experiments are shown (n = 3). *, p< 0.05; **, p < 0.01 when 
compared with controls at 37°C. 
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Figure 5. Cell viability in response to tert-BHQ (150-500 µM) after normothermic and 
hypothermic pre-incubation (24h) in MEF (A), HeLa (B) and HepG2 cells (C). Mean 
values (+SEM) from at least 16 independent experiments are shown (n = 16–18). Cell 
viability is normalized relative to the corresponding vehicle control at 37°C. Paired ob-
servations represent one biological replicate treated with tert-BHQ after normothermic 
and hypothermic pre-incubation. 
 
 
In order to gain insight into the dynamics of Nrf2 induction, HepG2 cells cons-
titutively expressing Nrf2 luciferase reporter were subjected to increasing dura-
tions of hypothermia. In parallel, antioxidant gene expression was monitored 
with real-time qPCR. Nrf2 reporter activity peaked at 8h and declined below the 
baseline level by 24h (Figure 6A). The expression dynamics of antioxidant 
system genes GCLC and TRXR1 (Figure 6B-C) correlated positively with Nrf2 
reporter activity (average Pearson Product-Moment correlation 0.86). The 
accuracy of Nrf2 reporter assay was confirmed by oxidative stress-inducing 
agents tert-BHQ and DL-Sulforaphane, which increased Nrf2 reporter activity 
and antioxidant N-acetylcysteine, which decreased it (Figure 6E).  No change in 
the expression of Nrf2 protein was observed after hypothermia on Western blot 
(Figure 6F) suggesting that hypothermia associated increase in Nrf2 activity 
might be due to a post-translational mechanism.  
 
?
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Figure 6. Time-course of Nrf2 luciferase reporter activity in HepG2 cells under hypo-
thermia (A). Time-course of GCLC (B) and TRXR1 (C) gene expression in HepG2 
under hypothermia. Cold-inducible gene CIRBP was used as positive control for hypo-
thermic effect (D). Activity of Nrf2 luciferase reporter in HepG2 cells in response to 
hypothermia and oxidative stress-modulating compounds (E). Activity is normalized 
relative to the corresponding vehicle control at 37°C. ROS-inducing compounds tert-
BHQ (150 µM), DL-Sulforaphane (3 µM) and antioxidant N-acetylcysteine (8 mM) 
were used as positive controls. All treatments were performed for 8h. Nrf2 protein 
expression in HepG2 cells under hypothermia and representative immunoblot (F). Tert-
BHQ (150 µM) was used as positive control for Nrf2 induction. All treatments were 
performed for 8 h. Mean values (+SEM) from at least three independent experiments 
are shown (n = 3–4). *, p < 0.05; **, p < 0.01 when compared with corresponding 
vehicle controls at 37°C or 0h time point. 
 
Next, we focused on HIF1Α, the major oxygen-dependent transcriptional acti-
vator (Elvidge et al., 2006; Forsythe et al., 1996; Manalo et al., 2005; Semenza 
and Wang, 1992), to explore the interplay between hypoxia-sensitive stress 
mechanisms and hypothermia. Under normoxic conditions, HIF1Α reporter 
activity increased monotonically in time when exposed to increasing durations 
of hypothermia (Figure 7A). Marked amplification of HIF1Α activity by hypo-
thermia was observed in CoCl2-treated cells and N-acetylcysteine abolished this 
effect (Figure 7B). Hypothermia in isolation increased HIF1Α protein abun-
dance modestly but significantly as measured by Western blot. When hypother-
mia was applied together with CoCl2, however, HIF1Α protein induction was 
amplified reminiscent of a synergistic effect (Figure 7C). Gene expression 
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analysis of HIF1Α target genes after 24h of normoxic hypothermia revealed no 
activation of BNIP3 and vascular endothelial growth factor A (VEGFA) (Figure 
7D-E), which are commonly induced under oxygen deprivation. These findings 
suggest that hypothermia can augment the activation of HIF1Α in hypoxia-
mimicking conditions. Furthermore, in normoxic settings, hypothermia in-
creases HIF1A activity without producing a downstream response typical of 
oxygen deprivation. 
 
 
Figure 7. Time-course of HIF1A luciferase reporter activity in HeLa cells under 
hypothermia (A). Activity of HIF1A luciferase reporter in response to hypothermia with 
respect to the corresponding vehicle control group at 37°C (B). Hypoxia mimetic CoCl2 
(100 µM) and antioxidant N-acetylcysteine (8 mM) were used as positive controls for 
HIF1A activity. All treatments were performed for 8 h. HIF1A protein expression in 
HeLa cells under hypothermia and representative immunoblot (C). CoCl2 (100 µM) was 
used as positive control for HIF1A induction. All treatments were performed for 8 h. 
Expression of BNIP3 (D) and VEGFA (E), HIF1-inducible genes, in HeLa cells under 
hypothermia (24 h). Mean values (+SEM) from three independent experiments are 
shown (n = 3). *, p < 0.05; **, p < 0.01 when compared with corresponding vehicle 
controls at 37°C or 0h time point. 
?
?
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1.3. Lower temperatures do not activate Nrf2 and  
HIF1A pathways as efficiently as 32°C 
Previous studies in animal models have suggested that relatively small de-
creases in body temperature are as protective as lower temperatures while not 
providing a mechanistic rationale for such observations (Krieger and Yenari, 
2004; van der Worp et al., 2007). We subjected cells to a temperature titration 
curve from 37ºC to 22ºC in 5ºC steps and measured the effect on Nrf2 and 
HIF1A activities and their downstream targets. Incubation at 27ºC or 22ºC did 
not increase Nrf2 and HIF1A transcription factor activities above the levels 
found at 32ºC (Figure 8A). Similarly, GCLC, TRXR1 and BNIP3 gene 
expression levels did not exhibit consistent temperature-dependent increase 
below 32ºC (Figure 8B–D). Incubation at 22ºC had no effect on Nrf2 activity 
and its downstream targets suggesting no additional benefits from lowering the 
temperature further. 
 
 
Figure 8. Response of Nrf2 and HIF1A luciferase reporters at various temperatures in 
HepG2 and HeLa cells, respectively (A). All treatments were performed for 8 h. Gene 
expression of GCLC (B), TRXR1 (C), and BNIP3 (D) at various temperatures in HeLa 
and HepG2 cells (8 h). Mean values (+SEM) of at least three independent experiments 
per cell line are shown (n = 3–4). *, p< 0.05; **, p < 0.01; ***, p < 0.001 when com-
pared with normothermic controls. 
?
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1.4. Mild hypothermia does not trigger unfolded protein  
response and inflammation 
Ischemic hypoxic injury perturbs ER homeostasis, leads to ER stress and con-
sequent activation of unfolded protein response (UPR) (Nakka et al., 2010; 
Tajiri et al., 2004). As hypothermia can decrease protein synthesis (Hofmann et 
al., 2012; Knight et al., 2015; Radford et al., 2015), possibly ameliorating ER-
stress, we studied its effect on transcriptional activators, which bind to the 
mammalian endoplasmic reticulum stress response element (ERSE). No in-
crease in ERSE reporter activity (Figure 9A) or in the level of X-box binding 
protein 1 (XBP1) spliced isoform (Figure 9B), which is translated to a potent 
transcription factor that binds to ERSE (Yoshida et al., 2001), was found in 
response to hypothermia. ER stress inducers tunicamycin and brefeldin A 
increased ERSE-driven luciferase activity approximately 1.5 – 1.65-fold (Figure 
9A). Furthermore, the induction of ERSE reporter activity by ER stress 
inducing compounds was attenuated by hypothermia (Figure 9A) suggesting 
that hypothermia is more likely to alleviate than to facilitate ER stress. 
 
 
 
 
Figure 9. Induction of ERSE-dependent luciferase reporter in HeLa cells in response to 
hypothermia (A). Activity is reported with respect to the vehicle control group at 37°C. 
ER-stress inducing compounds brefeldin A (5 µg/mL) and tunicamycin (5 µg/mL) were 
used as positive controls. All treatments were performed for 8 h. Expression of XBP1, 
an activating transcription factor 6 (Atf6) inducible gene, in HeLa cells in response to 
hypothermia (24 h) (B). Mean values (+SEM) of three independent experiments are 
shown (n = 3). *, p < 0.05; **, p < 0.01 when compared with corresponding vehicle 
controls at 37°C 
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NF-κB transcription factor plays a major role in inflammation and immune 
response. It is also involved in cell growth and apoptosis (Barkett and Gilmore, 
1999; Ghosh et al., 1998; Guttridge et al., 1999; Pahl, 1999). Hypoxia and ROS 
production both modulate NF-κB response (Koong et al., 1994a; 1994b; Shreck 
et al., 1992). We found TNFα, a pro-inflammatory cytokine, to activate NF-κB 
reporter activity 11-fold. In comparison, 1.6-fold induction of NF-κB reporter 
by hypothermia (Figure 10A) was not significantly different from the baseline 
(see HSV-TK reporter in Figure 2A). The expression level of cyclooxygenase 2 
(COX2) gene, a downstream target of NF-κB, appeared to be decreased by 
hypothermia (Figure 10B) supporting the notion that hypothermia is not a 
primary inducer of pro-inflammatory response in cells. 
 
 
 
 
Figure 10. Induction of NF-κB luciferase reporter in HepG2 cells in response to 
hypothermia with respect to the vehicle control group at 37°C (A). NF-κB -inducing 
compound TNFα (20 ng/mL) was used as positive control. All treatments were per-
formed for 8h. Expression of COX2, a NF-κB-inducible gene, in HepG2 cells in 
response to 24h hypothermia (B). Mean values (+SEM) from at least three independent 
experiments are shown (n = 3-4). *, p < 0.05; ***, p < 0.001 with respect to vehicle 
controls at 37°C. 
 
 
As hypothermia has become a routine clinical therapy for specific hypoxic/ 
ischemic conditions worldwide (Azzopardi et al., 2014; Bernard et al., 2002; 
HACA, 2002; Wagner et al., 1999), questions have arisen regarding the efficacy 
of current cooling protocols in providing optimal protection. In the past two 
years, a number of reviews have addressed this issue while paying little atten-
tion to the therapeutic mechanisms (Arrich et al., 2016; Chavez et al., 2016; 
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Dumitrascu et al., 2016; Gunn et al., 2016). Only a handful of studies have 
previously studied the role of signaling pathways in the therapeutic effects of 
hypothermia (Lee et al., 2017; Tahir and Pabaney, 2016; Talma et al., 2016) and 
the widely accepted mechanistic explanation is lacking in molecular detail. In 
general, proposed mechanisms rely on the conjecture that the reduction of 
metabolic demand in response to hypothermia leads to decreased oxidative 
stress, apoptosis, autophagy and inflammation (Lee et al., 2017; Talma et al., 
2016). Let us call this conjecture the thermodynamic hypothesis. First, one 
should note that apoptosis, autophagy and inflammation are likely to be 
secondary events triggered by cellular damage and, hence, it is not clear from 
the hypothesis whether therapeutic hypothermia affects these processes directly 
or by alleviating the root causes of cellular damage. Oxidative stress can be a 
potential root cause and hypothermia could mitigate it either by reducing the 
production of ROS (e.g. by reducing electron leak from the electron transport 
chain) or by enhancing the antioxidant response (e.g. by up-regulating reduced 
glutathione).  
There is, however, a more fundamental problem, which casts doubt on the 
thermodynamic hypothesis as a whole. If the thermodynamic hypothesis was to 
hold, one would expect larger therapeutic effects at lower temperatures (i.e. a 
positive correlation between therapeutic efficacy and temperature reduction) 
since it is well known that the metabolic rate of tissue is positively correlated 
with body temperature (not considering hyperthermia) (Chaui-Berlinck et al., 
2002; Geiser, 2004). Substantial body of evidence stands in conflict with this 
prediction, however, as the effect of therapeutic hypothermia peaks at around 
32ºC in mammals and no clear benefits arise from decreasing the temperature 
further (Bernard et al., 2002; Bona et al., 1998; Dalen et al., 2012; HACA, 
2002; Holzer, 2010; Wood et al., 2016). In line with these observations, we 
found no additional gain in HIF1A/Nrf2 activity and corresponding target gene 
expression at 27 and 22ºC when compared to 32ºC. These observations suggest 
a more complicated model where the efficacy of hypothermia possibly depends 
on a mechanism with inhibitory (e.g. the slowing down of metabolic rate) and 
activating (e.g. activation of stress mitigation pathways) components with the 
highest therapeutic effect emerging in the window of mild hypothermia (32–
35ºC). Our experiments with mild hypothermia revealed large-scale rearrange-
ments of gene expression in cell culture concomitant with the activation of 
transcription factors with potentially therapeutic downstream effects. It is 
conceivable that mild hypothermia is accompanied by metabolic adaptation, 
which boosts resilience to oxidative stress to deal with the negative effects of 
hypoxia and decreased energy expenditure (Alva et al., 2010; Camara et al., 
2004; Diestel et al., 2011; Huang et al., 2009; Maier et al., 2001). In hibernating 
species such as ground squirrels and bats, for example, metabolic adaptation to 
energy restriction has been shown to include upregulation of antioxidant 
proteins and glutathione (Carey et al., 2003; Storey, 2010; Yin et al., 2016).  
Our experiments in cell culture indicate that mild hypothermia triggers a 
temporary induction of Nrf2, the master regulator of antioxidant response, and 
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its target genes 8h after the onset followed by an increase in reduced glutathione 
level which is sustained at least 24h. Since the levels of oxidized glutathione 
were not affected by hypothermia, the up-regulation of cellular glutathione 
should be interpreted as an increase in antioxidant potential (i.e. a proactive 
effect) and not a reaction to elevated oxidative stress. Furthermore, we found 
that hypothermic pretreatment (24h) increased the viability of MEFs and HeLa 
cells subjected to oxidative stress. To my knowledge, we are the first to report 
evidence that hypothermia effect can translate into the activation of the anti-
oxidant system on three levels of the hierarchy 1) Nrf2 transcription factor acti-
vation 2) up-regulation of Nrf2 target genes 3) up-regulation of reduced 
glutathione. 
Another therapeutically relevant effect of hypothermia was revealed in our 
experiments with the HIF1 reporter, where hypothermia amplified HIF1 induc-
tion when applied together with the hypoxia-mimetic CoCl2. Hypothermic 
facilitation of HIF1 response to hypoxic stress is likely to speed up the cascade 
of metabolic adaptations such as switching to anaerobic ATP production by 
diverting glucose degradation to lactate and reduction of mitochondrial mass 
(Semenza, 2011; Zhang and Bosch, 2008). 
On the other hand, hypothermia had negligible impact on the activity ER 
stress and NF-kB reporters suggesting that immune signaling (Han et al., 2002; 
Webster et al., 2009; Yenari and Han, 2006) and ER stress pathways (Aoki et 
al., 2001; Poone et al., 2015) are unlikely to be among the primary targets of 
therapeutic hypothermia in cells. 
 
 
2. Paper II 
2.1. Endogenous H2S influences cardiac mitochondrial content 
We sought to determine if there was a direct relationship between the cardiac 
H2S levels and mitochondrial content. First, we used a genetic model to address 
this question. We collected heart samples from mice with significantly elevated 
levels of H2S (CSE Tg+) and from mice with attenuated levels of H2S (CSE KO) 
(Supplemental Figure 1, paper II). Analysis revealed that the hearts of CSE Tg+ 
mice displayed an increase in mitochondrial DNA levels and citrate synthase 
activity (Figure 11A–B). In contrast, both were decreased in the hearts of CSE 
KO mice. Together these findings suggest that H2S levels influence cardiac 
mitochondrial content. This was further confirmed by analysis of electron 
microscopy images of cardiac ventricles from CSE Tg+ and CSE KO mice 
demonstrating an increase and decrease in the number of mitochondria per field, 
respectively (Figure 11C–D). 
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Figure 11. (A) Ratio of mitochondrial DNA to nuclear DNA. (B) Citrate synthase acti-
vity. (C) Representative electron microscopy images of mitochondria. Scale bar equals 
3 μm. (D) Number of mitochondria per field of view. (E) Summary of mitochondria 
area and perimeter measurements (μm2) and (F) percentage of mitochondria in a given 
field that fell into three size categories based on area: < 0.6 μm2, 0.6 μm2–1.0 μm2, and 
> 1.0 μm2. (G) Basal and maximum (state 3) oxygen consumption rates for perme-
abilized myocardial fibers in the presence of pyruvate and (H) palmitoyl-l-carnitine. (I) 
Efficiency of ATP synthesis [ATP produced per oxygen consumed (ATP/O)] in 
permeabilized myocardial fibers. All samples were collected from hearts of Wild-Type, 
cystathionase-γ-lyase transgenic (CSE Tg+), and CSE deficient (CSE KO) mice. Values 
are means ± SEM. Numbers in bars indicate sample size. *p < 0.05, **p < 0.01, and 
***p < 0.001 vs. Wild-type. 
 
 
Alterations in mitochondrial content can arise from biogenesis or from fusion 
and fission. A series of experiments were, therefore, undertaken to determine 
the contribution of fusion-fission to the altered mitochondrial content observed 
in the hearts of CSE Tg+ and CSE KO mice (Supplemental Figure 2, paper II). 
First, the expression of proteins involved in mitochondrial fusion and fission 
were evaluated. The expression of the fusion proteins, Mfn1, Mfn2, and Opa-1, 
as well as the fission protein, fission-1 (Fis1) were not altered in the hearts of 
CSE Tg+ or CSE KO mice. Second by electron microscopy, we observed no 
differences in the area or perimeter of the mitochondria in the hearts of each 
strain (Figure 11E). Finally, further analysis of mitochondrial fusion-fission was 
achieved by calculating the percentage of mitochondria in a given field that fell 
into three size categories based on area: < 0.6 μm2, 0.6 μm2–1.0 μm2, and  
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> 1.0 μm2 (Wang et al., 2011). In support of the overall area and perimeter 
calculations, this analysis also revealed no differences in the hearts of each 
strain (Figure 11F). Overall these results suggest that H2S levels influence 
cardiac mitochondrial content via biogenesis. 
To characterize the mitochondrial functional phenotype of hearts from WT, 
CSE Tg+ and CSE KO mice in a manner that would detect potential differences 
in mitochondrial volume density or function, respiration (oxygen consumption) 
experiments were performed on saponin-permeabilized myocardial fibers. This 
technique can measure the maximal respiratory capacity of specific mito-
chondrial oxidative pathways via selective use of different metabolic substrates 
(Lehman et al., 2008). Experiments were performed with LV fibers using 
pyruvate and palmitoyl-carnitine. For these experiments, basal respiration was 
assessed followed by maximal ADP-stimulated state 3 respiration. LV fibers 
from CSE Tg+ mice did not display any changes in state 3 respiration rates in 
the presence of pyruvate (Figure 11G). They did however display increased 
state 3 respiration rates in the presence of palmitoyl-carnitine (Figure 11H). In 
contrast, LV fibers from CSE KO mice displayed increased state 3 respiration 
rates in the presence of pyruvate and decreased rates in the presence of 
palmitoyl-carnitine. Additionally, maximal rates of ATP synthesis from ADP 
were normalized to state 3 respiration rates to determine the efficacy of ATP 
synthesis in the presence of each substrate (Figure 11I). LV fibers from CSE 
Tg+ mice displayed enhanced ATP/oxygen ratios in the presence of palmitoyl-
carnitine. In contrast, fibers from CSE KO mice displayed lower ATP/oxygen 
ratios in the presence of both pyruvate and palmitoyl-carnitine. 
 
 
2.2. Exogenous H2S influences cardiac mitochondrial biogenesis 
Next, we sought to determine if exogenous H2S could influence cardiac mito-
chondrial content. For these studies, we administered SG-1002 (20 mg/kg/day) 
in the chow for 4 weeks. SG-1002 is an H2S prodrug that we have previously 
shown to exert cardioprotective effects (Kondo et al 2013; Barr et al., 2015). 
Initial studies confirmed that the administration of SG-1002 significantly in-
creased cardiac H2S levels (Supplemental Figure 1, paper II). We then 
examined if the increase in H2S influenced cardiac mitochondrial content. 
Analysis revealed that SG-1002 increased mitochondrial DNA levels, citrate 
synthase activity, and the number of mitochondria per field of electron micro-
scopy images (Figure 12A–D). Further analysis confirmed that SG-1002 did not 
influence mitochondrial fusion-fission (Supplemental Figure 2, paper II and 
Figure 12E–F). Finally, SG-1002 did not alter the state 3 respiration rates of LV 
fibers in the presence of pyruvate (Figure 12G). It did, however, improve the 
state 3 respiration rates and ATP/oxygen ratios of LV fibers in the presence of 
palmitoyl-carnitine (Figure 12H–I). 
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Figure 12. (A) Ratio of mitochondrial DNA to nuclear DNA. (B) Citrate synthase 
activity. (C) Representative electron microscopy images of mitochondria. Scale bar 
equals 3 μm. (D) Number of mitochondria per field of view. (E) Summary of mito-
chondria area and perimeter measurements (μm2) and (F) percentage of mitochondria in 
a given field that fell into three size categories based on area: < 0.6 μm2, 0.6 μm2–1.0 μm2, 
and > 1.0 μm2. (G) Basal and maximum (state 3) oxygen consumption rates for per-
meabilized myocardial fibers in the presence of pyruvate and (H) palmitoyl-l-carnitine. 
(I) Efficiency of ATP synthesis [ATP produced per oxygen consumed (ATP/O)] in 
permeabilized myocardial fibers. All samples were collected from hearts of mice 
administered standard diet (Chow) or diet supplemented with SG-1002 (SG-1002;  
20 mg/kg/day) for 4 weeks. Values are means ± SEM. Numbers in bars indicate sample 
size. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. Chow. 
 
 
2.3. H2S levels influence PGC1α 
Given that PGC-1α is a master regulator of mitochondrial biogenesis (Kubli et 
al., 2012; Fernandez-Marcos et al., 2011), we sought to determine if H2S in-
fluenced the expression or activation of PGC-1α. Initial analysis revealed that 
the whole cell expression of PGC-1α was not altered in the hearts of CSE Tg+ or 
CSE KO mice (Figure 13A–B). However, the cytosolic levels of PGC-1α were 
significantly lower in the hearts of CSE Tg+ mice (Figure 13A–B). Correspon-
48 
dingly, the nuclear levels of PGC-1α were significantly higher in the hearts of 
CSE Tg+ mice. In contrast, the cytosolic levels of PGC-1α were unaltered in the 
hearts of CSE KO mice. However, the nuclear levels of PGC-1α were signi-
ficantly lower in the hearts of CSE KO mice (Figure 13A–B). In agreement 
with these changes, the hearts of CSE Tg+ mice displayed elevated expression 
of a number of PGC-1α target genes, whereas the expression of the same genes 
were lower in the hearts of CSE KO mice (Figure 13D). Similarly, SG-1002 did 
not alter the whole cell expression of PGC-1α, but it did decrease the cytosolic 
levels of PGC-1α, increase the nuclear expression of PGC-1α, and increase the 
expression of PGC-1α target genes (Figure 13D–F). Together, this data suggests 
that cardiac H2S levels influence the nuclear localization and transcriptional 
activity of PGC-1α. 
 
 
Figure 13. (A) Representative immunoblots and (B) analysis of the whole cell, cyto-
solic and nuclear expression of PGC1α. (C) Relative gene expression of PGC1α target 
genes associated with mitochondrial biogenesis (tfam, cox4i1, cox1, atp5b). Samples 
were collected from Wild-Type, CSE Tg+, and CSE KO mice. Values are means ± 
SEM. *p < 0.05 and **p < 0.01 vs. Wild-type. (D) Representative immunoblots and (E) 
analysis of the whole cell, cytosolic and nuclear expression of PGC1α. (F) Relative gene 
expression of PGC1α target genes associated with mitochondrial biogenesis (tfam, 
cox4i1, cox1, atp5b). Samples were collected from mice administered Chow or diet 
supplemented with SG-1002. Values are means ± SEM. Numbers in bars indicate 
sample size. *p < 0.05 vs. Chow. 
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2.4. H2S induces mitochondrial biogenesis via AMPK 
The transcriptional activity of PGC-1α is regulated by post-translational modi-
fications. For instance, AMPK regulates the transcriptional activity of PGC-1α 
via phosphorylation (Jager et al., 2007), whereas Sirt1 regulates its transcriptio-
nal activity via deacetylation (Fernandez-Marcos et al., 2011). Evidence 
suggests that AMPK both activates Sirt1 and cooperates with it in enhancing the 
ability of PGC-1α to stimulate mitochondrial biogenesis (Yan et al., 2013). So, 
the next series of experiments sought to determine if H2S-induced mitochondrial 
biogenesis was channeled through AMPK and Sirt1. SG-1002 increased the 
phosphorylation and activity of AMPK (Figure 14A–C). No changes were 
observed in the expression of Sirt1, but SG-1002 did increase its activity 
(Figure 14D–F). In agreement with these changes, SG-1002 increased the serine 
phosphorylation of PGC-1α and decreased its acetylation (Figure 14G–I). To 
determine if AMPK was directly responsible for H2S induced PGC-1α-signaling 
and mitochondrial biogenesis, αMHC-Cre+ x AMPKfl/fl mice were given SG-
1002 for 4 weeks. The deficiency of AMPK did not affect the expression of 
PGC-1α or Sirt1 (Figure 15A–C). However, SG-1002 failed to increase the 
serine phosphorylation of PGC-1α, failed to increase Sirt1 activity, and failed to 
decrease the acetylation of PGC-1α (Figure 15D–H). Importantly, SG-1002 was 
unable to increase the expression of PGC-1α target genes and mitochondrial 
DNA levels in the hearts of αMHC-Cre+ x AMPKfl/fl mice (Figure 15I). 
Together this data suggests that H2S induced mitochondrial biogenesis via an 
AMPK-Sirt1-PGC-1α signaling cascade. 
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Figure 14. (A–B) Representative immunoblots and analysis of phosphorylated AMPK 
and total AMPK. (C) AMPK activity. (D–E) Representative immunoblots and analysis 
of Sirt1. (F) Sirt1 activity. (G) Representative immunoblots and analysis from immuno-
precipitation experiments examining the (H) serine phosphorylation and (I) acetylation 
status of PGC1α. All samples were collected from hearts of mice administered standard 
diet (Chow) or diet supplemented with SG-1002 (SG-1002; 20 mg/kg/day) for 4 weeks. 
Values are means ± SEM. Numbers in bars indicate sample size. *p < 0.05 and  
**p < 0.01 vs. Chow. 
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Figure 15. (A) Representative immunoblots and analysis of (B) PGC1α and (C) Sirt1. 
(D) Representative immunoblots and analysis from immunoprecipitation experiments 
examining the serine phosphorylation status of PGC1α. (E) Sirt1 activity. (F) Repre-
sentative immunoblots and analysis from immunoprecipitation experiments examining 
the acetylation status of PGC1α. (G) Relative gene expression of tfam, cox4i1, and 
mitochondria DNA. All samples were collected from hearts of Wild-type (αMHC-Cre+) 
and αMHC-Cre+ x AMPK floxed (αMHC-Cre+ x AMPKfl/fl) mice administered standard 
diet (Chow) or diet supplemented with SG-1002 (SG; 20 mg/kg/day) for 4 weeks. 
Values are means ± SEM. Numbers in bars indicate sample size.  *p < 0.05, **p < 0.01, 
and ***p < 0.001 vs. WT Chow. 
 
 
2.5. H2S levels and mitochondria content are reduced  
in response to heart failure 
There is evidence for impaired mitochondrial biogenesis from animal models of 
heart failure and from studies utilizing human heart failure samples (Karaman-
lidis et al., 2010; Arany et al., 2006). Additionally, studies report lower circu-
lating H2S levels in human heart failure patients (Polhemus et al., 2014). How-
ever, an association between cardiac H2S levels and cardiac mitochondrial con-
tent has not been explored. Here, we were able to obtain LV samples from end-
stage heart failure patients at the time of transplant. Analysis revealed di-
minished H2S levels (Figure 16A–B), as well as lower levels of PGC-1α target 
genes (Figure 16C) and mitochondrial DNA levels (Figure 16D). Similar results 
in regards to H2S levels and mitochondrial content were also found in samples 
from mice collected at 2 weeks following myocardial ischemia and reperfusion 
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(Figure 17A–C). We, therefore, sought to determine if restoring H2S levels 
could influence the mitochondrial content of the ischemic heart via the proposed 
AMPK-PGC1α signaling cascade. Mice subjected to myocardial ischemia and 
reperfusion were administered normal diet or diet supplemented with SG-1002 
beginning 24 h after reperfusion. The mice were then followed for 2 weeks. Our 
analysis revealed that restoring H2S levels via the dietary supplementation of 
SG-1002 was associated with an increase in the phosphorylation of AMPK, an 
increase in the gene expression of PGC-1α target genes, an increase in cardiac 
mitochondrial content, improved mitochondrial respiration, improved ATP 
production efficiency, and improved cardiac dilatation and function (Figure 
17C–H and Supplemental Figure 6F–H, paper II). 
 
 
 
Figure 16. Cardiac levels of (A) free H2S and (B) sulfane sulfur. (C) Relative gene 
expression of atp5b, mt-co1, and tfam. (D) Ratio of mitochondrial DNA to nuclear 
DNA. LV samples were collected from non-failing and end stage heart failure patients. 
Number in bars represent sample sizes. Values are means ± SEM. Numbers in bars 
indicate sample size. *p < 0.05 and ***p < 0.001 vs. Non-Failing. 
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Figure 17. Cardiac levels of (A) free H2S and (B) sulfane sulfur. (C) Ratio of mito-
chondrial DNA to nuclear DNA. (D) Basal and maximum (state 3) oxygen consumption 
rates for permeabilized myocardial fibers in the presence of palmitoyl-l-carnitine. (E) 
Efficiency of ATP synthesis [ATP produced per oxygen consumed (ATP/O)] in per-
meabilized myocardial fibers. Samples were collected from hearts of mice subjected to 
60 min of ischemia and 2 weeks of reperfusion. Values are means ± SEM. *p < 0.05, 
**p < 0.01, and ***p < 0.001 vs. Sham. (F) LV end-diastolic diameter (LVEDD), LV 
end-systolic diameter (LVESD), and LV Ejection Fraction measured in groups of mice 
using echocardiography images 2 weeks following myocardial ischemia and reperfusion 
(Post). Values are means ± SEM. Numbers in bars indicate sample size. ***p < 0.001 
vs. Baseline. 
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The transcriptional activity of PGC-1α is regulated by a number of stimuli, 
exemplifying the range of settings in which mitochondrial biogenesis is in-
duced. The mechanisms governing this regulation have been extensively studied 
and have been determined to vary between tissues and different settings 
(Fernandez-Marcos et al., 2011). AMPK, a member of the metabolite-sensing 
protein kinase family, is activated in response to alterations in cellular energy 
levels (Zaha et al., 2012). Activation of AMPK acts to maintain cellular energy 
stores, switching on catabolic pathways that produce ATP, while switching off 
anabolic pathways that consume ATP (Canto et al., 2009). AMPK also induces 
mitochondrial biogenesis via the activation of PGC-1α. Specifically, AMPK 
regulates PGC-1α directly through serine phosphorylation, as well as indirectly 
via the activation of Sirt1, which leads to the deacetylation of PGC-1α 
(Fernandez-Marcos et al., 2011). This coordinated signaling cascade, whereby 
the phosphorylation of PGC-1α by AMPK is required for the subsequent Sirt1-
mediated deacetylation, demonstrates the complex and specific nature by which 
PGC-1α is regulated by AMPK (Nisoli et al., 2004). Here, we found that in-
creasing cardiac H2S levels through the dietary supplementation of SG-1002 led 
to the activation of AMPK and Sirt1 resulting in the phosphorylation and 
deacetylation of PGC-1α. More importantly, we found that SG-1002 failed to 
alter PGC-1α, induce PGC-1α target genes, and induce mitochondrial bio-
genesis in the hearts of AMPKα2 deficient mice – indicating that H2S induces 
mitochondrial biogenesis via AMPK.  
As noted, H2S is a known regulator of cellular bioenergetics via its actions 
on mitochondrial function. For instance, H2S acts as a stimulator of mitochond-
rial bioenergetics through its ability to donate electrons to the mitochondrial 
electron transport chain (Modis et al., 2013a; Fu et al., 2012). This action serves 
a physiological role in the maintenance of mitochondrial electron transport, as 
well as complementing and balancing the bioenergetic role of Krebs cycle-
derived electron donors (Modis et al., 2013a). In contrast, H2S is a potent and 
reversible inhibitor of mitochondrial function via its regulation of cyto-
chrome c oxidase (complex IV of the mitochondrial electron transport chain) 
(Hill et al., 1984). Paradoxically, this action contributes to the cardioprotective 
effects of exogenous H2S, as inhibition of mitochondrial respiration during the 
early stages of reperfusion injury limits the generation of ROS, which ultima-
tely preserves mitochondrial function (King et al., 2014; Calvert et al., 2010b; 
Elrod et al., 2007). In addition, H2S targets several cellular pathways that 
influence mitochondrial function (Modis et al., 2013b). PGC-1α not only 
regulates mitochondrial biogenesis, but also regulates energy expenditure in the 
heart. Specifically, PGC-1α is essential for the maintenance of maximal, effi-
cient cardiac mitochondrial fatty acid oxidation and ATP synthesis (Lehman et 
al., 2008). Consistent with our findings regarding the induction of PGC-1α sig-
naling, we observed that augmenting cardiac H2S levels increased the maximal 
capacity for mitochondrial fatty acid β-oxidation and ATP synthesis, whereas 
lower H2S levels had the opposite effect. 
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The AMPK-PGC-1α signaling cascade has been extensively studied in the 
context of cardiac metabolism (Zaha et al., 2012). Current study provides novel 
evidence that endogenous and exogenous H2S modulates mitochondrial bio-
genesis via AMPK-PGC-1α signaling. Furthermore, the finding that a decrease in 
endogenous H2S levels led to an impairment in AMPK-PGC-1α signaling be-
comes important when considering the evidence that H2S levels are decreased in 
pathological conditions – i.e. heart failure (Fig. 15 and (Polhemus et al., 2014)) – 
that also present with reduced mitochondrial content (Karamanlidis et al., 2010; 
Arany et al., 2006). Based on this evidence it can be suggested that endogenous 
H2S levels not only play an important role in maintaining the mitochondrial 
content of the heart, but that a reduction in endogenous H2S levels contributes to 
the pathophysiology of heart failure through a disruption in mitochondrial 
biogenesis. This idea is supported by our findings that restoring H2S levels with 
SG-1002 increased mitochondrial content, improved ATP production, and 
attenuated LV dysfunction in a murine model of ischemia reperfusion injury.  
 
 
3. Paper III 
3.1. Kinetics of lymphangiogenesis early after the onset of  
myocardial ischemia 
Previous studies report an endogenous lymphangiogenesis in response to myo-
cardial ischemia (Klotz et al., 2015; Henri et al., 2016). However, the kinetics of 
the response have not been evaluated during the early period following the onset 
of ischemia. We, therefore, addressed this here. For these experiments, mice were 
subjected to permanent myocardia ischemia and followed for up to 7 days. First, 
we assessed the protein expression of VEGF-C and VEGFR3 in heart homo-
genates obtained from mice subjected to various periods of ischemia (Figure 18). 
The expression of VEGF-C was significantly increased 1 day after the onset of 
ischemia. This increase persisted for up to 7 days of ischemia. The expression of 
VEGFR3 was increased from 3 days to 7 days of ischemia. Next, we evaluated 
the remodeling of the cardiac lymphatics by focusing on the lymph density in the 
subendocardium (an area that experiences a robust increase in lymphatic density 
in response to myocardial ischemia (Henri et al., 2016). Our analysis revealed a 
significant increase in the number of LYVE1 positive cells starting at 3 days of 
ischemia that persisted for up to 7 days of ischemia (Figure 19A–B). To 
investigate if the observed increase in LYVE1 positive cells was indicative of 
lymphatic cell proliferation, we treated a subset of mice with BrdU starting after 
the onset of myocardial ischemia. Analysis revealed a significant increase in the 
number of LYVE1 positive cells labeled with BrdU starting at 3 days of ischemia 
with a gradual increase noted at 7 days of ischemia (Figure 19C). Finally, we also 
evaluated the diameter of lymphatic pre-collectors in the epicardium as an 
evaluation of lymphatic drainage capacity (Henri et al., 2016). Our analysis 
revealed a significant increase in lumen area starting at 1 day of ischemia that 
persisted for up to 7 days of ischemia (Figure 19A and D). 
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Figure 18. Representative immunoblots and analysis of (A) VEGF-C and (B) VEGFR3 
protein expression levels in samples collected from hearts subjected to different periods 
of ischemia. Values are means ±SEM. Numbers in bars indicates sample size. *p<0.05,  
**p<0.01, and ***p<0.001 vs. Sham. MI, myocardial ischemia. 
 
 
 
Figure 19. Representative images of LV sections stained with an anti-LYVE1 antibody 
to denote LYVE1 positive cells (top row) and lymphatic collecting vessel luminal area.  
(B) Summary of LYVE1 positive cells. (C) Summary of LYVE1 positive cells labeled 
with BrdU. (D) lymphatic lumen area. Samples were collected from hearts subjected to 
different periods of ischemia. Scale bar denotes 50 µm(A) or 20 µm (C). Values are 
means ±SEM. Numbers in bars indicate sample size. *p<0.05, **p<0.01 and ***p<0.001 
vs. Sham. 
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3.2.  Kinetics of lymphangiogenesis in the setting of myocardial 
ischemia reperfusion injury 
The next series of experiments evaluated the kinetics of the lymphangiogenesis 
response in a more clinically relevant model of myocardial ischemia reperfusion 
injury. For these experiments, mice were subjected to 60 minutes of myocardial 
ischemia followed by up to 7 days of reperfusion. First, we assessed the protein 
expression of VEGF-C and VEGFR3 in heart homogenates obtained from mice 
subjected to ischemia and to various periods of reperfusion (Figure 20). The 
expression of VEGF-C was significantly increased 1 day after reperfusion. This 
increase persisted for up to 7 days of reperfusion with a peak elevation observed 
at 3 days of reperfusion. The expression of VEGFR3 was likewise increased 
from 1 day to 7 days of reperfusion. However, the increase was similar at all 
times evaluated. Additional analysis revealed a significant increase in the 
number of LYVE1 positive cells starting at 3 days of reperfusion that persisted 
for up to 7 days of reperfusion (Figure 21A–B). Finally, we noted a significant 
increase in epicardial lymphatic lumen area starting at 3 days of reperfusion that 
persisted for up to 7 days of reperfusion (Figure 21A and C). 
 
 
 
Figure 20. Representative immunoblots and analysis of (A) VEGF-C and (B) VEGFR3 
protein expression levels in samples collected from hearts subjected to 60 minutes of 
myocardial ischemia and different periods of reperfusion. Values are means ±SEM. 
Numbers in bars indicate sample size. *p<0.05,  **p<0.01, and ***p<0.001 vs. Sham. 
I/R, ischemia and reperfusion. 
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Figure 21. (A) Representative images of LV sections stained with an anti-Lyve1 anti-
body to denote Lyve1 positive cells (top row) and lymphatic collecting vessel luminal 
area. Summary of (B) Lyve1 positive cells and (C) lymphatic lumen area. Samples were 
collected from hearts subjected to 60 minutes of myocardial ischemia and different pe-
riods of reperfusion. Scale bar denotes 50 µm. Values are means ±SEM. Numbers in 
bars indicate sample size. **p<0.01 and ***p<0.001 vs. Sham. 
 
 
3.3. Blocking endogenous lymphangiogenesis response exacerbates 
ischemic-induced heart failure. 
As noted, previous studies have reported that treatment with VEGF-C augments 
endogenous lymphangiogenesis and leads to improvements in cardiac function 
in rat models of permanent myocardial ischemia and myocardial ischemia reper-
fusion (Klotz et al., 2015; Henri et al., 2016). However, there is not any infor-
mation available linking the consequences of inhibiting the endogenous 
lymphangiogenesis response to the development of heart failure. We, therefore, 
addressed this issue using two different pharmacological approaches. In the first 
set of experiments, mice were subjected to 60 minutes of ischemia followed by 
reperfusion. At the time of reperfusion, a hydrogel containing the VEGFR3 
inhibitor, MAZ-51, was placed on the surface of the infarcted myocardium prior 
to the closing of the chest cavity. Mice treated with MAZ-51 displayed a signi-
ficant decrease in subendocardial lymph density at 7 days of reperfusion when 
compared to vehicle treated mice (Figure 22A–B). Given that the lymphatic 
system functions in the clearance of inflammatory cells and edema (Alitalo, 
2011; Bryere and Noel, 2010; Karaman and Detmar, 2014), we next evaluated 
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the relationship in the development of lymphatic vessels and the inflammatory 
response following MAZ-51 treatment. First, we observed a significant increase 
in the diameter of epicardial lymphatic pre-collectors in MAZ-51-treated hearts 
when compared to vehicle treated mice (Figure 22A and C). This was as-
sociated with the accumulation of B lymphocytes (detected as B220 and IgM 
double positive cells) (Zouggari et al., 2013) and an increase in the levels of 
TNFα, IL-1b, and IL-6 (Figure 23A–E). In the second set of experiments, 
different groups of mice had a hydrogel containing a VEGF-C NAb placed on 
the surface of the infarcted myocardium. In a similar manner to MAZ-51, treat-
ment with VEGF-C NAb led to a decrease in subendocardial lymph density 
(Figure 22A–B), an increase in the diameter of epicardial lymphatic pre-
collectors (Figure 22A and C), and an increase in the inflammatory response at 
7 days of reperfusion (Figure 23A-E). Postischemic cardiac remodeling and 
dysfunction are closely linked to inflammation. (Frangogiannis, 2012) We, 
therefore, investigated the effects of MAZ-51 and VEGF-C NAb treatment on 
cardiac remodeling and dysfunction. Analysis at 28 days of reperfusion revealed 
that both treatments increased infarct scar size, increased ventricular hyper-
trophy, increased LV dilatation, and decreased LV function (Figure 24).  
 
 
Figure 22. (A) Representative images of LV sections stained with an anti-Lyve1 
antibody to denote Lyve1 positive cells (top row) and lymphatic collecting vessel 
luminal area. Summary of (B) Lyve1 positive cells and (C) lymphatic lumen area. 
Samples were collected from hearts subjected to 60 minutes of myocardial ischemia and 
1 week of reperfusion. Different groups of mice were treated with Vehicle, MAZ-51, 
VEGF-C neutralizing antibody (NAb), or VEGF-CCys156Ser. Scale bar denotes 50 µm. 
Values are means ±SEM. Numbers in bars indicate sample size. *p<0.05 and 
***p<0.001 vs. Sham. 
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Figure 23.  (A) Representative images of LV sections stained with B220 and IgM to 
denote inflammatory cells. Bar denotes 50 µm. (B) Summary of B220 and IgM positive 
cells. Levels of (C) TNFα, (D) IL-1b, and (E) IL-6. Samples were collected from hearts 
subjected to 60 minutes of myocardial ischemia and 1 week of reperfusion. Different 
groups of mice were treated with Vehicle, MAZ-51, VEGF-C neutralizing antibody 
(NAb), or VEGF-CCys156Ser. Values are means ±SEM. Numbers in bars indicate sample 
size. *p<0.05, **p<0.01, and ***p<0.001 vs. Sham. 
 
 
3.4. Enhancing endogenous lymphangiogenesis response attenuates 
ischemic-induced heart failure 
Next, we sought to determine the therapeutic potential of a VEGF-C releasing 
hydrogel in the setting of myocardial ischemia reperfusion injury. For these 
experiments, mice were subjected to 60 minutes of ischemia followed by reper-
fusion. At the time of reperfusion, a hydrogel containing VEGF-CCys156Ser (a 
mutant form that specifically binds to VEGF-R3 (Joukov et al., 1998) was 
placed on the surface of the infarcted myocardium prior to the closing of the 
chest cavity. Mice treated with VEGF-CCys156Ser displayed a significant increase 
in subendocardial lymph density at 7 days of reperfusion when compared to 
vehicle treated mice (Figure 22A–B). This was associated with a decrease in the 
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diameter of epicardial lymphatic pre-collectors (Figure 22A and C), a decrease 
in the accumulation of B lymphocytes (Figure 23A–B), and a decrease in the 
levels of TNFα, IL-1b, and IL-6 (Figure 23C-E) when compared to vehicle 
treated mice. Further analysis at 28 days of reperfusion revealed that VEGF-
CCys156Ser treatment decreased infarct scar size, decreased ventricular hyper-
trophy, decreased LV dilatation, and increased LV function (Figure 24).  
 
Figure 24. (A) Representative images of heart sections stained with Masson’s trichrome 
to denote infarct scar. (B) Infarct scar area as a percentage of LV area. (C) Heart weight 
to tibia length ratios (HW:TL). Values are means ±SEM. *p<0.05, **p<0.01, and 
***p<0.001 vs. Vehicle. (D) Left ventricular end-diastolic diameter (LVEDD), (E) LV 
end-systolic diameter (LVESD), and (F) LV ejection fraction were measured in groups 
of mice using echocardiography images 4 weeks following myocardial ischemia and 
reperfusion (Post). Values are means ±SEM. Numbers in bars indicate sample size. 
***p<0.001 vs. Baseline. 
 
 
The molecular and cellular events initiated with hours to days following the 
onset of myocardial infarction dictate the ultimate consequences of the injury. 
Therefore, it is important to understand early signaling events that contribute to 
myocardial damage and repair (Rainer et al., 2014). Following the onset of 
ischemic injury, cardiomyocytes undergo irreversible injury leading to cell 
death. The initiation of a highly regulated inflammatory response consisting of 
neutrophils and monocytes/macrophages occurs with hours after the insult to 
remove dead cells and matrix debris (Jung et al., 2013; Swirski et al., 2013; 
Frangogiannis, 2006). As a result, the temporal sequence of events occurring 
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after the onset of ischemic injury must be finely tuned to promote healing while 
at the same time minimizing adverse remodeling (Rainer et al., 2014).  
The functional significance of the cardiac lymphatic system was first 
demonstrated by the observation that surgical ligation of a lymphatic vessel in 
the canine heart induced edema, cardiac fibrosis and cardiac dysfunction (Kline 
et al., 1963). This was further substantiated by the observations that obstructing 
lymphatic flow following myocardial ischemia exacerbated ischemic-induced 
edema, fibrosis and cardiac dysfunction (Kline et al., 1964). However, until 
recently, few advances in our understanding of the physiological role of the 
cardiac lymphatic system have been made. In the past several years, two elegant 
studies have independently demonstrated that myocardial ischemia induces an 
endogenous lymphangiogenesis response (Klotz et al., 2015; Henri et al., 2016). 
In the current study, we confirm these results in mouse models of myocardial 
ischemia and ischemia reperfusion injury. In our study, we focused on the 
kinetics of the endogenous lymphangiogenesis response during the early periods 
following either the onset of ischemia or reperfusion. Although we found a 
similar response in regards to an increase in the protein expression of VEGF-C 
and VEGFR3 preceding an increase in subendocardial lymph density, there was 
a subtle difference between the two models. Specifically, we observed a 
difference in the kinetics of VEGF-C expression. In the ischemia model, VEGF-
C was elevated to a similar level at all times evaluated. In contrast, the expres-
sion of VEGF-C rose dramatically at 3 days of reperfusion before declining to a 
lower level by 5 days of reperfusion. Currently, the underlying cause for this 
difference is not known. However, the difference did not seem to influence the 
endogenous lymphangiogenesis response, as a similar pattern and onset of an 
increase in subendocardial lymph density was observed in both models. Our 
findings are in slight contrast with those previously reported (Klotz et al., 2015; 
Henri et al., 2016). Specifically, the previous studies reported that the endo-
genous lymphangiogenesis response occurs weeks after the onset of myocardial 
ischemia. Currently, we do not completely understand the conflicting observa-
tions regarding the timing of the response. However, it should be noted that the 
previous studies used a rat model of myocardial ischemia and focused on later 
time points.  Here, we used a mouse model and focused on the early periods 
following the onset of ischemia or reperfusion. Despite the differences in timing 
all 3 findings clearly indicate that the response occurs.  
In agreement with the two previous studies (Klotz et al., 2015; Henri et al., 
2016), we also found that treatment with a mutated version of VEGF-C aug-
mented the endogenous lymphangiogenesis response and attenuated ischemic-
induced cardiac dysfunction. Specifically, we found that VEGF-CCys156Ser treat-
ment increased ischemic-induced subendocardial lymph density and decreased 
inflammation at 7 days of reperfusion. This was associated with a reduction in 
scar formation and improvement in cardiac function at 28 days of reperfusion. 
More importantly, we provide direct evidence that blocking the endogenous 
lymphangiogenesis response exacerbates cardiac injury and dysfunction 
following myocardial ischemia reperfusion. As noted, signaling via VEGF-C 
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and VEGFR3 are the most central pathway for lymphangiogenesis. Here, we 
found that inhibiting VEGFR3 with MAZ-51 blunted the ischemic-induced 
increase in subendocardial lymph density, increased inflammation, increased 
scar formation, and increased cardiac dysfunction. Likewise, targeting endo-
genous VEGF-C with a NAb disrupted the endogenous lymphangiogenesis 
response and exacerbated cardiac injury. Together, this data suggests that the 
endogenous lymphangiogenesis response plays an adaptive role in response to 
myocardial ischemia reperfusion injury.  
 
4. Concluding remarks and future directions  
The clinical manifestations of ischemia reperfusion injury are diverse. Even 
more, the process of reperfusion is a ʻdouble-edge sword’ and can, in itself, 
induce cell death. From a treatment standpoint, ischemia reperfusion injury is a 
critical challenge. We have shown three interventions that are capable of 
reducing ischemia reperfusion injury such as hypothermia, hydrogen sulfide and 
lymphangiogenesis (Figure 25). Therapeutic modalities can be categorized 
according to the time of application. Hypothermia treatment is normally 
administered during ischemia (Yenari and Hemmen, 2010; Yenari and Han, 
2012). In our settings, diet supplemented with SG-1002 began 24 h after reper-
fusion and gelatin hydrogels containing VEGF-C were placed on the surface of 
myocardium after the onset of reperfusion. Hypothermia may protect against 
ongoing ischemic injury and blunt the immediate hyperaemia (Yenari and Han, 
2012). Since most cell death occurs during the first minutes of reperfusion, 
treatments that protect only against reperfusion injury should be administered as 
early as possible. In fact, hypothermia applied together with interventions 
against reperfusion injury (e.g. hydrogen sulfide or lymphangiogenesis) may 
protect the heart from ongoing ischemic injury and reduce damage caused by 
restoration of blood flow.  
Therapeutic strategies can also be classified according to their end target. 
The first group includes molecular targets involved in cell death, such as 
necrosis, apoptosis, reactive oxygen species, and autophagy. Hypothermia 
(Frink et al., 2012; Yenari and Han, 2012) and hydrogen sulfide (Wu et al., 
2015) are known to target these pathways. However, there has been some 
controversy on the role of H2S in autophagy (Wu et al., 2018). Second group 
includes activation of signaling pathways related to cytoprotective response, 
pro-survival, and mitochondrial function. Again, hypothermia and hydrogen 
sulfide target this group. Third group includes inflammation and all here studied 
therapeutics reduce inflammation (Szuba et al., 2002; Kataru et al., 2009; Frink 
et al., 2012; Yenari and Han, 2012; Shimizu et al., 2012; Wu et al., 2015; Henri 
et al., 2016).  
Protective strategies can also be catecorized based on the cellular target. 
Hypothermia affects virtually all organ systems. In the heart, hydrogen sulfide 
is produced in the myocardium, blood vessels and fibroblasts (Andreadou et al., 
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2015; Calvert et al., 2010b; Polhemus and Lefer, 2014). VEGF-C binds to 
VEGFR-3 on lymphatic endothelial cells and to either VEGFR-3 or vascular 
endothelial growth factor receptor 2 (VEGFR-2) on blood endothelial cells 
(Brakenhielm and Alitalo, 2009; Cao et al., 1998; Joukov et al., 1997; Henri et 
al., 2016).  
Translation of individual therapeutic to clinical settings has controversy 
results (Doukas et al., 2006; Garcia-Prieto et al., 2017). Combination of 2 or 
more interventions, each which has different time point of action (during 
ischemia, at reperfusion, and late into reperfusion), distinct target and end-point 
may provide additive benefits and maximal protection.  
 
Figure 25. Graphical overview of therapeutic strategies for ischemia reperfusion injury 
investigated in the present study. IRI – ischemia reperfusion injury, NAb – neutralizing 
antibody, HRE – hypoxia response element, ARE – antioxidant response element, P – 
phosphorylation, Ac – acetylation 
 
 
Therapeutic hypothermia is one of the most promising future interventions for 
the treatment of ischemic injury. However, the mechanisms of action are diver-
se and not completely understood. Hypothermia is probably able to modify the 
cascade of ischemic events on many levels. Firstly, knowing the mechanisms of 
action would allow to plan more controlled clinical trials and evaluate syner-
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gistic effects of therapeutic hypothermia combined with other existing therapies. 
Secondly, the development of drugs designed to target therapeutically relevant 
pathways would eliminate the confounding effects associated with body 
cooling. We argue that systems coping with cellular stressors are plausible 
targets of therapeutic hypothermia and deserve more attention in clinical hypo-
thermia research. Hypothermia had a major impact on Nrf2 and HIF1a signaling 
pathways suggesting that antioxidant system and hypoxia response are likely to 
be among the primary candidates for testing. H2S is one of the potential options 
to treat ischemia reperfusion. An accumulating body of evidence shows that 
exogenous or endogenous H2S have cardioprotective effects (Bian et al., 2006; 
Elrod et al., 2007; Sivarajah et al., 2006; Bliksoen et al., 2008; Johansen et al., 
2006; Calvert et al., 2010b; Sodha et al., 2008; Osipov et al, 2009; Ji et al., 
2008). Numerous proteins and pathways have been identified as cellular targets 
of H2S (Calvert et al., 2009; Elrod et al., 2007; Hausenloy et al., 2006; Hu et al., 
2008; Jha et al., 2008; Kondo et al., 2013; Kaiser et al., 2004; Luan et al., 2012; 
Wang et al., 2011). However, a common cellular target for many studies aimed 
at understanding the biology and therapeutic potential of H2S has been the 
mitochondria (Aon et al., 2004; Barr et al., 2015; Calvert et al., 2010a; Calvert 
et al., 2010b; Chen et al., 2006; Elrod et al., 2007; Kind et al., 2014; Kondo et 
al., 2013; Minamishima et al., 2009; Pan et al., 2014; Polhemus et al., 2013; 
Untereiner et al., 2016; Wang et al., 2011). H2S has a dual effect on mito-
chondrial bioenergetics with low concentrations serving as electron donors to 
the electron transport chain and higher concentrations serving as inhibitors of 
cytochrome c oxidase (Hill et al., 1984; Modis et al., 2013a; Fu et al., 2012). 
We showed here that H2S is an important regulator of cardiac mitochondrial 
content and requires AMPK to induce PGC1α signaling and mitochondrial bio-
genesis. In addition, we found that restoring H2S levels with SG-1002 in the 
setting of heart failure increased cardiac mitochondrial content, improved 
mitochondrial respiration, improved ATP production efficiency, and improved 
cardiac function. Our study has, therefore, identified a potentially important 
regulatory mechanism in the mitochondrial biogenesis pathway that if corrected 
by restoring H2S levels could protect the failing heart and ultimately reduce 
mortality and morbidity associated with heart failure. Future studies aimed at 
determining if H2S therapy coupled with other pharmacological agents that 
target the AMPK-PGC-1α signaling pathway are warranted to fully test this 
postulate. In recent years, there has been a growing interest in lymphatic 
research due to several key breakthroughs into the biology of lymphatic 
endothelial cells. The discovery of VEGF-C, and its receptor, VEGFR3 (Lohela 
et al., 2009), followed by the identification of proteins that discriminate between 
endothelial cells of the blood and lymphatic vessel lineages (i.e. LYVE-1) 
(Tammela et al., 2010), lead to the understanding that lymphatic vessels serve 
an active role in disease processes (Alitalo, 2011; Bruyere and Noel, 2010; 
Karaman and Detmar, 2014). Current findings provide evidence that the endo-
genous lymphangiogenesis response is induced within 3 days following myo-
cardial ischemia. Moreover, we provide evidence that the response plays an 
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adaptive role in the development of ischemic-induced heart failure. Thus, our 
findings support the emerging concept that therapeutic lymphangiogenesis is a 
promising new approach for the treatment of cardiovascular disease (Henri et 
al., 2016). We anticipate that the clinical use of therapeutic lymphangiogenesis 
will not be achieved by systemic delivery, but rather local delivery. As such, the 
use of hydrogels could be a viable delivery strategy. Due to their highly tunable 
chemical, physical, and mechanical properties, hydrogels have been widely used 
as a tool in regenerative medicine (Hastings et al., 2015; Slaughter et al., 2009). 
In regards to the heart, hydrogel-based materials have been used as a structural/ 
mechanical support for the injured myocardium (Fujimoto et al., 2009) and have 
also been used as a means to deliver small molecules (Zustiak et al., 2013). The 
ability to fine-tune the properties of the hydrogel provides the unique oppor-
tunity to control the delivery of pharmacological agents (Slaughter et al., 2009). 
Here, we used a hydrogel to deliver VEGF-CCys156Ser to the injured myocardium 
by placing the gel on the surface of the heart. While this strategy might not be 
clinically feasible, it does show proof of concept that the delivery mechanism is 
viable. As such, future approaches such as injecting the VEGF-C containing 
hydrogel directly into the myocardium are warranted. 
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CONCLUSIONS 
1.  Traditionally, hypothermia is considered as a passive rather than active agent 
in shaping cellular physiology. In paper I, it is shown that, contrary to the 
predictions of the thermodynamic hypothesis, mild hypothermia can activate 
regulatory factors that govern cellular coping with stressors. It is demonstrated 
for the first time that mild hypothermia (32°C) activates major transcription 
factors Nrf2 and HIF1A, which orchestrate adaptive responses to hypoxic 
stress. Evidence suggesting that hypothermia is able to augment stress res-
ponse in mammalian cell lines motivates to inspect corresponding mecha-
nisms more closely in animal studies. 
2.  H2S is an important regulator of mitochondrial bioenergetics, but its role in 
regulating mitochondrial biogenesis is not well understood. Mice deficient in 
the H2S-producing enzyme, cystathionine γ-lyase (CSE KO) display 
diminished cardiac mitochondrial content when compared to wild-type 
hearts. In contrast, mice overexpressing CSE (CSE Tg) and mice supple-
mented with the orally active H2S-releasing prodrug, SG-1002, display en-
hanced cardiac mitochondrial content. Studies aimed at evaluating the under-
lying mechanisms found that H2S requires AMPK to induce PGC1α 
signaling and mitochondrial biogenesis. Finally, restoring H2S levels with 
SG-1002 in the setting of heart failure increases cardiac mitochondrial 
content, improved mitochondrial respiration, improved ATP production effi-
ciency, and improved cardiac function.  
3.  Although the lymphatic system has been known to exist in a heart, very little 
is known about the role the cardiac lymphatic system plays in the develop-
ment of heart failure. Results revealed that both, myocardial ischemia or 
myocardial ischemia and reperfusion, increase VEGF-C and VEGFR3 pro-
tein expression starting at 1 day following the onset of injury, whereas a 
significant increase in lymphatic vessel density is observed starting at 3 
days. Further studies aimed to determine the consequences of inhibiting the 
endogenous lymphangiogenesis response on the development of heart fai-
lure. Using two different pharmacological approaches, it was found that 
inhibiting VEGFR3 with MAZ-51 and blocking endogenous VEGF-C with a 
NAb blunts the increase in lymphatic vessel density, increased inflammation, 
and increased cardiac dysfunction. Subsequent studies revealed that augmen-
tation of the endogenous lymphangiogenesis response with VEGF-C treat-
ment reduces inflammation, and improved cardiac dysfunction. These results 
suggest that the endogenous lymphangiogenesis response plays an adaptive 
role in the development of ischemic-induced heart failure. 
Taken together, it is likely that no single intervention can provide exten-
sive protection against such a complex event like ischemia reperfusion injury 
with many interlinked processes. It is important that a potential course of 
treatment addresses all major aspects of this pathological condition while 
being appropriately timed to ensure a complete protection against ischemia 
reperfusion injury. 
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SUMMARY IN ESTONIAN 
Isheemia reperfusiooni kahjustuse terapeutilised mehhanismid 
Hüpoksilis-isheemilist seisundit põhjustavad ajukahjustus, südameinfarkt, süda-
me seiskumine ja hüpoksilis-isheemiline entsefalopaatia vastsündinutel. Hetkel 
kasutusel olevad ravimeetodid aitavad küll vähendada kahjustust, kuid pole 
kaugeltki ideaalsed. Hapniku ja verevoolu taastamine aitavad kõrvaldada tekki-
nud kahjustuse. See kõrvaldab esmalt tekkinud kahjustuse, kuid põhjustab 
omakorda reperfusiooni kahjustuse, mille tagajärjed võivad olla tõsisemad kui 
isheemial üksi. Ideaalne ravimeetod võimaldaks taastada verevoolu võimalikult 
väikese reperfusiooni kahjustusega. Selleks, et välja töötada tõhusamaid ravi-
meetodeid on meil vaja paremini mõista molekulaarseid mehhanisme, mis on 
seotud isheemia reperfusiooni kahjustusega. Käesolev doktoritöö koosneb kol-
mest artiklist, milles uurisime kolme erinevat terapeutilist mehhanismi (hüpo-
termia, vesiniksulfiid ja lümfangiogenees). Antud töö aitab paremini mõista, 
millised tegurid võiks kaitsta kude hapnikupuuduse eest, mis kaasneb erinevate 
südameveresoonkonna haigustega. 
Esimene artikkel annab uut informatsiooni hüpotermia molekulaarsete 
toimemehhanismide kohta. Kliinikus on hüpotermia (32°C) kasutusel eelkõige 
kesknärvisüsteemi hüpoksilis-isheemiliste kahjustuste leevendamiseks. Kuna 
hüpotermial on võime kaitsta rakku isheemilise seisundi korral, siis on selle 
molekulaarsete mehhanismide tuvastamine äärmiselt oluline.  Meie töö näitab 
esmakordselt, et mõõdukas hüpotermia (32°C) aktiveerib transkriptsiooni-
faktoreid nagu Nrf2 ja HIF1A, mis vahendavad adaptiivset vastust hüpoksilisele 
stressile. Hüpotermiat on seni vaadatud kui passiivset termodünaamilist tegurit 
(vähendab metabolismi ja hapniku tarbimist) raku füsioloogia mõjutamisel. 
Meie viimased tulemused viitavad aga sellele, et hüpotermia kutsub esile iseloo-
muliku vastuse raku füsioloogias spetsiifiliste molekulaarsete regulaatorite 
vahendusel, misläbi suureneb stressile vastupanu olukorras, kus puudub hapnik.  
Teises artiklis uurisime, kas vesiniksulfiid võib mõjutada südames mito-
kondrite hulka. Vesiniksulfiid on mitokondrite bioenergeetikas oluline regu-
laator, kuid selle roll mitokondrite biogeneesi regulatsioonis on ebaselge. Tsüs-
tationiini γ-lüaasi puudulikel (CSE KO) hiirtel puudub vesiniksulfiidi tootev 
ensüüm. Nendel hiirtel on südames vähenenud mitokondrite hulk võrreldes 
metsiktüüpi hiirtega. Samas CSE üleekspressioon ja vesiniksulfiidi vabastava 
eelravimi, SG-1002, manustamine suurendavad mitokondrite hulka. Leidsime, 
et vesiniksulfiidi tase südames mõjutab PGC1α tuuma lokalisatsiooni ja trans-
kriptsioonilist aktiivsust. Lisaks vajab vesiniksulfiid AMPK-d, et indutseerida 
PGC1α signaal ja mitokondrite biogenees. Meie tulemused näitavad ka, et kui 
taastada SG-1002-ga vesiniksulfiidi tase südamekahjustuse olukorras, siis suu-
reneb südame mitokondrite hulk, paraneb mitokondrite hingamine, ATP tootlik-
kuse efektiivsus ja südame funktsioon. Koos näitavad need tulemused, et 
vesiniksulfiid on südame mitokondrite koguse oluline regulaator ja eksogeenne 
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vesiniksulfiid indutseerib mitokondrite biogeneesi läbi AMPK-PGC1α signaali-
raja.  
Kolmas artikkel aitab paremini kirjeldada südame lümfaatilise süsteemi rolli 
südame isheemia-reperfusiooni kahjustuse korral. Selleks tekitati hiirtele müo-
kardi isheemia või isheemia-reperfusiooni kahjustus, mis kestis kuni 28 päeva. 
Meie tulemused näitavad, et mõlemad isheemiamudelid stimuleerivad endo-
geenset lümfangiogeneesi suurendades VEGF-C (vascular endothelial growth 
factor C) ja VEGFR3 (VEGF receptor 3) valgu ekspressiooni juba päev pärast 
kahjustust. Lümfisoonte tihedus suureneb alates kolmandast päevast. Järgmi-
seks inhibeerisime endogeense lümfangiogeneesi südamekahjustuse olukorras. 
Leidsime, et selle tagajärjel ei suurenenud lümfisoonte tihedus, vaid suurenes 
põletikuvastus ning südame düsfunktsioon (talitushäire). Samas on äärmiselt 
oluline leid, kus VEGF-C manustamine vähendas põletikku ja parandas südame 
talitushäiret. Nende tulemuste põhjal saab järeldada, et endogeensel lümfo-
angiogeneesil on adaptiivne roll südamepuudulikkuse tekkes ja terapeutiline 
lümfangiogenees on üks lootustandvamaid ravimeetodeid kardiovaskulaarsete 
haiguste ravis. 
Ilmselgelt on isheemia-reperfusiooni kahjustuse näol tegemist väga komp-
leksse haigusseisundiga, kus interakteeruvad omavahel erinevad molekulaarsed 
signaalirajad. Seega ei ole antud olukorras ühte kindlat ravimeetodit, mis aitaks 
toime tulla tekkinud kahjustusega. Pigem on see kombinatsioon mitmest erine-
vast terapeutilisest mehhanismist, mille koostoime vähendab isheemia-reperfu-
siooni kahjustust.  
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